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  Improvements	   in	  healthcare	  and	  nutrition	  have	  generated	  remarkable	   increases	   in	   life	  expectancy	  worldwide.	  This	  is	  one	  of	  the	  greatest	  achievements	  of	  the	  modern	  world	  yet	  it	   also	   presents	   a	   grave	   challenge:	   as	   more	   people	   survive	   into	   later	   life,	   more	   also	  experience	  the	  diseases	  of	  old	  age,	  including	  type	  2	  diabetes,	  cardiovascular	  disease	  and	  cancer.	  Developing	  new	  ways	  to	  improve	  health	  in	  the	  elderly	  is	  therefore	  a	  top	  priority	  for	   biomedical	   research.	   Whilst	   our	   understanding	   of	   the	   molecular	   basis	   of	   these	  morbidities	  has	  advanced	  rapidly,	  effective	  novel	  treatments	  are	  still	  lacking.	  Alternative	  drug	  development	  strategies	  are	  now	  being	  explored	  such	  as	  the	  repurposing	  of	  existing	  drugs	   used	   to	   treat	   other	   diseases.	   This	   can	   save	   a	   considerable	   amount	   of	   time	   and	  money	   since	   the	   pharmacokinetics,	   pharmacodynamics	   and	   safety	   profiles	   of	   these	  drugs	   are	   already	   established,	   effectively	   enabling	   preclinical	   studies	   to	   be	   bypassed.	  Metformin	   is	   one	   such	   drug	   currently	   being	   investigated	   for	   novel	   applications.	   This	  review	  provides	   a	   thorough	   and	  detailed	   account	   of	   our	   current	   understanding	   of	   the	  molecular	   pharmacology	   and	   signalling	   mechanisms	   underlying	   biguanide-­‐protein	  interactions.	   It	   also	   focuses	   on	   the	   key	   role	   of	   the	   microbiota	   in	   regulating	   age-­‐associated	   morbidities	   and	   a	   potential	   role	   for	   metformin	   to	   modulate	   its	   function.	  Research	   in	   this	   area	   holds	   the	   key	   to	   solving	   many	   of	   the	   mysteries	   of	   our	   current	  understanding	   of	   drug	   action	   and	   concerted	   effects	   to	   provide	   sustained	   and	   long-­‐life	  health.	  	  	  
	   	  
Introduction	  The	   biguanide	  metformin	   is	   the	  most	   commonly	   prescribed	   drug	   for	   type	   2	   diabetes	  (T2D)	  taken	  by	  an	  estimated	  150	  million	   individuals	  worldwide.	   It	   is	  derived	  from	  the	  plant	  Galega	  officinalis	  (French	  lilac),	  which	  has	  a	  history	  as	  a	  herbal	  remedy	  that	  can	  be	  traced	  back	  to	  medieval	  Europe	  when	  it	  was	  used	  to	  relieve	  symptoms	  now	  attributed	  to	  diabetes	   [1].	   In	   the	   late	   1800s,	  G.	  officinalis	  was	   discovered	   to	   be	   rich	   in	   guanidine,	   a	  compound	   that	   was	   subsequently	   shown	   to	   have	   hypoglycaemic	   properties	   [2].	  However,	   the	   toxicity	   of	   guanidine	   precluded	   its	   clinical	   use	   and	   attention	   shifted	  towards	   safer	   analogues.	   The	   biguanides,	   consisting	   of	   two	  N-­‐linked	   guanidines,	  were	  synthesised	  in	  the	  1920s	  but	  their	  therapeutic	  potential	  was	  initially	  overlooked	  due	  to	  the	   introduction	   of	   insulin	   therapy	   in	   the	   same	   decade.	   It	   was	   not	   until	   1957	   that	  metformin	  was	  recommended	  for	  the	  treatment	  of	  diabetes	  following	  the	  publication	  of	  a	   successful	   trial	   by	   the	   French	   physician	   Jean	   Sterne	   [1].	   Unlike	   the	   pre-­‐existing	  diabetes	  therapies,	  biguanides	  had	  the	  advantage	  of	  being	  able	  to	  reduce	  blood	  glucose	  levels	  without	  inducing	  hypoglycaemia.	  At	  first,	  the	  more	  potent	  biguanides	  phenformin	  and	  buformin	  received	  the	  greatest	  popularity,	  however	  increasing	  reports	  of	  associated	  lactic	  acidosis	   led	  to	  these	  drugs	  being	  withdrawn	  from	  the	  markets	  of	  most	  countries	  during	   the	   1970s	   [3].	  Due	   to	   its	   superior	   safety	   profile,	  metformin	   eventually	   became	  established	   as	   the	   first-­‐line	   treatment	   for	   T2D	   and	   it	   is	   now	   featured	   on	   the	   World	  Health	  Organisation’s	  list	  of	  essential	  medicines	  [4].	   	   	   	   	  	   Interestingly,	   the	   therapeutic	   potential	   of	   metformin	   treatment	   extends	   far	  beyond	   its	  prescribed	  use	  as	  an	  anti-­‐diabetic	  drug.	  There	   is	  a	   rapidly	  growing	  body	  of	  literature	   demonstrating	   an	   effective	   role	   for	  metformin	   in	   the	   treatment	   of	   multiple	  diseases	   including	  cancer	  and	  cardiovascular	  disease.	  Additionally	   there	   is	  evidence	  to	  suggest	   that	   metformin	   delays	   the	   ageing	   process	   and	   modulates	   the	   microbiota	   to	  promote	  health.	  How	  metformin	   is	  capable	  of	  achieving	  such	  pleiotropic	  actions	   is	  not	  yet	   fully	   understood.	   Here,	   we	   will	   review	   the	   molecular	   mechanisms	   proposed	   to	  explain	  these	  diverse	  effects.	  	  
Metformin	  and	  Type	  2	  Diabetes	  According	  to	  the	  latest	  global	  estimates,	  there	  are	  382	  million	  people	  are	  currently	  living	  with	   diabetes	   [5].	   Increasing	   urbanisation	   and	   the	   accompanying	   rise	   in	   obesity	   and	  sedentary	   behaviour	  mean	   that	   this	   figure	   is	   expected	   to	   reach	   592	  million	   by	   2035,	  presenting	  national	  healthcare	  systems	  with	  an	  overwhelming	  challenge.	  T2D	  accounts	  for	  between	  85-­‐95%	  of	  diabetes	  cases	  and	  is	  characterised	  by	  hyperglycaemia	  resulting	  from	   insulin	   resistance	   or	   impaired	   insulin	   secretion.	   It	   is	   a	   disorder	  with	   a	   complex	  aetiology	   involving	   interactions	   between	   multiple	   genetic	   and	   environmental	   factors.	  Strong	   predictors	   include	   family	   history,	   increased	   body-­‐mass	   index,	   high	   blood	  pressure,	  physical	  inactivity,	  poor	  diet	  and	  advancing	  age	  [6].	  In	  the	  long-­‐term,	  T2D	  can	  give	  rise	  to	  several	  disabling	  and	  life-­‐threatening	  complications	  such	  as	  cardiovascular	  disease,	  neuropathy,	  retinopathy	  and	  nephropathy	  [7].	  The	  onset	  of	  these	  complications	  can	   be	   prevented	   or	   significantly	   delayed	   by	   effective	   management	   of	   blood	   glucose	  levels,	  which	   is	  achieved	  through	   lifestyle	  modifications,	  and	   in	  many	  cases,	   the	  use	  of	  oral	  anti-­‐hyperglycaemic	  agents	  such	  as	  metformin.	  	   Despite	   being	   first	   introduced	   as	   a	   treatment	   for	   T2D	   in	   1957,	   metformin’s	  mechanism	  of	  action	   is	  not	  yet	   fully	  understood.	  The	  drug’s	  anti-­‐hyperglycaemic	  effect	  has	  been	  partly	  attributed	  to	  increased	  hepatic	  insulin	  sensitivity	  and	  elevated	  uptake	  of	  glucose	   in	   peripheral	   tissues,	   however	   it	   is	   now	  widely	   accepted	   that	  metformin	   acts	  predominantly	   via	   suppression	   of	   hepatic	   gluconeogenesis.	   It	   has	   been	   reported	   that	  metformin	  can	  lower	  the	  rate	  of	  gluconeogenesis	  by	  as	  much	  as	  36%	  in	  diabetic	  patients	  [8].	   Nevertheless,	   the	   molecular	   pathways	   responsible	   for	   this	   reduction	   of	   glucose	  production	  remain	  a	  subject	  of	  debate.	  
	  
Molecular	  target	  of	  metformin	  Due	   to	   its	   unusually	   hydrophilic	   nature,	   metformin	   is	   unable	   to	   passively	   diffuse	  through	   cell	  membranes	   and	  must	   rely	   on	  members	   of	   the	   organic	   cation	   transporter	  (OCT)	   family	   for	   uptake	   into	   hepatocytes.	   Specifically,	   OCT1	   has	   been	   shown	   to	   be	  essential	   for	   the	   therapeutic	   efficacy	   of	   metformin,	   and	   it	   has	   been	   suggested	   that	  genetic	  polymorphisms	  in	  human	  OCT1	  may	  contribute	  to	  variation	  in	  clinical	  response	  to	   the	  drug	  [9].	  Once	   it	  has	  entered	  the	  hepatocyte,	  metformin	  accumulates	  within	  the	  mitochondrial	   matrix.	   It	   is	   likely	   that	   this	   uptake	   results	   from	   the	   positively	   charged	  molecule	   being	   driven	   by	   the	   membrane	   potential	   of	   energised	   mitochondria	   [10].	  Additionally,	  interactions	  may	  take	  place	  between	  metformin’s	  apolar	  hydrocarbon	  side	  chain	   and	   the	   hydrophobic	   phospholipids	   of	   the	   mitochondrial	   membrane	   [11].	   It	   is	  generally	  agreed	  that	  complex	  I	  of	  the	  mitochondrial	  respiratory	  chain	  is	  a	  key	  target	  of	  metformin.	  This	  stems	  from	  the	  work	  of	  two	  independent	  research	  groups	  who	  reported	  that	   metformin	   selectively	   inhibits	   the	   oxidation	   of	   complex	   I	   substrates	   but	   not	  complex	   II	   or	   IV	   substrates	   [10,	   12].	   Although	   these	   findings	   were	   first	   observed	   in	  isolated	   rat	   hepatocytes,	   similar	   results	   have	   since	   been	   obtained	   in	   numerous	   cell	  models	  including	  primary	  human	  hepatocytes	  [13].	  	   It	  is	  not	  known	  exactly	  how	  metformin	  inhibits	  complex	  I,	  although	  it	  is	  possible	  that	  the	  metal-­‐binding	  properties	  of	  the	  drug	  may	  be	  implicated.	  It	  has	  been	  shown	  that	  the	   elevated	   pH	   of	   the	  mitochondrial	  matrix	   converts	  metformin	   into	   a	   deprotonated	  form	   with	   a	   high	   affinity	   for	   copper	   ions	   [14].	   These	   copper	   complexes	   have	   the	  potential	  to	  interfere	  with	  the	  sensitive	  redox	  reactions	  of	  the	  respiratory	  chain.	  This	  is	  consistent	  with	   the	  earlier	   finding	   that	   the	   cellular	  effects	  of	  metformin	  depend	  on	   its	  ability	   to	   bind	   copper	   [15].	   An	   alternative	  mechanism	   to	   account	   for	   the	   inhibition	   of	  complex	   I	   by	   metformin	   has	   recently	   been	   described	   by	   Bridges	   et	   al	   [16].	   They	  demonstrated	   that	   metformin	   inhibits	   ubiquinone	   reduction	   in	   a	   non-­‐competitive	  manner,	  possibly	  by	  binding	  at	  the	  interface	  of	  the	  hydrophilic	  and	  membrane	  domains	  and	   trapping	   the	  enzyme	   in	  a	  deactive-­‐like	  open-­‐loop	  conformation.	   It	   is	  worth	  noting	  that	  although	  the	   inhibitory	  effect	  of	  metformin	   is	   largely	  confined	  to	  complex	   I,	  other	  biguanides	  have	  been	  found	  to	  inhibit	  several	  respiratory	  chain	  enzymes	  and	  therefore	  collectively	  this	  class	  of	  drugs	  is	  best	  considered	  non-­‐specific	  [16,	  17].	  	   The	   consequence	   of	   complex	   I	   inhibition	   by	   metformin	   is	   a	   decline	   in	   ATP	  production	  accompanied	  by	  a	  concomitant	  increase	  in	  ADP	  and	  AMP	  levels.	  This	  altered	  cellular	  energy	  charge	   is	  detected	  by	   the	   cell’s	  principle	  energy	   sensor,	  AMP-­‐activated	  protein	  kinase	  (AMPK).	  Whether	  or	  not	  AMPK	  is	  a	  central	  mediator	  of	  metformin	  action	  is	   a	   controversial	   issue	   and	   both	   AMPK-­‐dependent	   and	   independent	   models	   will	   be	  outlined	  here.	  	  	  
AMPK-­‐dependent	  mechanism	  AMPK	   is	  a	  master	   regulator	  of	   cellular	  energy	  homeostasis	   that	   is	  activated	  by	  the	  binding	  of	  an	  ADP	  or	  AMP	  molecule	  to	  a	  site	  on	  its	  regulatory	  γ	  subunit	  [18,	  19].	  This	  enables	   the	   cell	   to	   respond	   to	   falling	   energy	   status	   by	   transforming	   it	   from	   an	   ATP-­‐consuming	  anabolic	  state	  into	  an	  ATP-­‐producing	  catabolic	  state.	  	  	   A	  key	  role	   for	  AMPK	   in	   the	  mechanism	  of	  metformin	  action	  was	  established	   in	  2001	   following	   the	   publication	   of	   an	   influential	   study	   by	   Zhou	   et	   al.	   [20].	   They	  demonstrated	   that	  metformin	   stimulates	   AMPK	   activation	   in	   rat	   primary	   hepatocytes	  and	  used	  the	  AMPK	  inhibitor	  compound	  C	  to	  show	  that	  AMPK	  is	  required	  for	  the	  drug’s	  inhibitory	   effect	   on	   glucose	   production	   [20],	   however	   it	   should	   be	   noted	   that	   this	  inhibitor	  was	   later	   found	   to	  be	  non-­‐selective.	  Nevertheless,	   these	   initial	   findings	  were	  supported	  by	  a	  subsequent	  study	  by	  Shaw	  et	  al.,	  which	   found	  that	   loss	  of	  hepatic	   liver	  kinase	  B1	   (LKB1),	   an	  upstream	  activator	  of	  AMPK	   responsible	   for	  phosphorylating	   its	  catalytic	   α	   subunit,	   abolished	   the	   glucose-­‐lowering	   effects	   of	  metformin	   in	  mice	   fed	   a	  high-­‐fat	  diet	  [21].	  
	   It	  was	  suggested	  that	  this	  LKB1/AMPK	  pathway,	  activated	  by	  metformin,	  alters	  the	   cell’s	   gluconeogenic	   programme	   via	   inhibition	   of	   cAMP	   response	   element	   binding	  protein	   (CREB)	   regulated	   transcription	   coactivator	   2	   (CRTC2)	   –	   a	   pivotal	   regulator	   of	  gluconeogenic	  gene	  expression	   [21].	   In	   its	  non-­‐phosphorylated	  state,	  CRTC2	   is	   located	  in	   the	   nucleus	   where	   it	   associates	   with	   CREB	   to	   upregulate	   the	   transcription	   of	  peroxisome	  proliferator-­‐activated	  receptor	  gamma	  coactivator	  1-­‐alpha	  (PGC-­‐1α)	  and	  its	  downstream	   target	   genes	   phosphoenolpyruvate	   carboxykinase	   and	   glucose-­‐6-­‐phosphatase.	   However,	   AMPK	   can	   stimulate	   the	   phosphorylation	   of	   CRTC2	   at	   Ser171	  resulting	   in	   its	   nuclear	   exclusion	   [21].	   Alternatively,	   the	   disabling	   of	   CRTC2	   may	   be	  achieved	  via	  AMPK-­‐mediated	  induction	  of	  nicotinamide	  phosphoribosyltransferase	  and	  the	   accompanying	   increase	   in	   hepatic	   sirtuin	   1	   (SIRT1).	   Deacetylation	   of	   CRTC2	   by	  SIRT1	  leaves	  it	  vulnerable	  to	  constitutive	  photomorphogenesis	  1-­‐mediated	  ubiquination	  and	   degradation,	   the	   consequence	   of	   which	   is	   inhibition	   of	   gluconeogenic	   gene	  expression	  [22].	  It	  has	  also	  been	  shown	  that	  AMPK	  triggers	  the	  dissociation	  of	  the	  CREB-­‐CREB	  binding	  protein	  (CBP)-­‐CRTC2	  transcription	  complex	  via	  phosphorylation	  of	  CBP	  at	  Ser436	  [23].	  	  	   Despite	   showing	   initial	   promise,	   AMPK’s	   status	   as	   the	   major	   mediator	   of	  metformin’s	  action	  was	  seriously	  undermined	  following	  the	  publication	  of	  work	  carried	  out	   by	   Foretz	   et	   al.	   in	   2010.	   In	   this	   study,	   metformin	   was	   found	   to	   inhibit	   glucose	  production	   normally	   in	   transgenic	   mice	   lacking	   hepatic	   AMPK	   catalytic	   subunits	   or	  LKB1	   [24].	   It	   was	   suggested	   that	   the	   discrepancy	   between	   this	   result	   and	   the	   early	  findings	   of	   Shaw	  et	  al.	  was	   due	   to	   the	   fact	   that	   in	   the	   latter	   study,	   the	   direct	   effect	   of	  metformin	   on	   hepatic	   glucose	   output	  was	   not	   assessed.	   Instead	   they	   investigated	   the	  effect	  of	  repeated	  metformin	  administration	  on	  fasting	  blood	  glucose	  levels.	  Therefore,	  these	  results	  may	  actually	   reflect	  an	   indirect	  effect	  of	   the	  AMPK/LKB1	  axis	  on	  hepatic	  glucose	   production,	   potentially	   caused	   by	   AMPK’s	   suppression	   of	   lipogenesis	   [24].	   A	  well-­‐known	   target	   of	   AMPK	   is	   acetyl-­‐CoA	   carboxylase	   (ACC);	   a	   rate-­‐limiting	   enzyme	  required	  for	  the	  generation	  of	  malonyl-­‐CoA,	  which	  is	  both	  a	  precursor	  of	  lipogenesis	  and	  an	  inhibitor	  of	  β-­‐oxidation.	  The	  inhibition	  of	  ACC	  by	  AMPK	  has	  been	  shown	  to	  regulate	  metformin-­‐induced	   improvements	   in	   insulin	   action	   in	  mice	   [25].	   Furthermore,	   AMPK	  can	   down-­‐regulate	   the	   expression	   of	   multiple	   lipogenic	   genes	   by	   inhibiting	   the	  transcriptional	   activity	   of	   sterol	   regulatory	   element-­‐binding	   protein	   1	   (SREBP-­‐1)	   [20]	  and	  carbohydrate-­‐responsive	  element-­‐binding	  protein	  (ChREBP)	  [26].	  Therefore,	  even	  if	  AMPK	  is	  dispensable	  for	  the	  glucose-­‐lowering	  action	  of	  metformin,	  it	  could	  contribute	  to	  the	   therapeutic	   effects	   of	   the	   drug	   in	   the	   longer	   term	   by	   inducing	   favourable	  modifications	  of	  lipid	  metabolism	  that	  help	  to	  increase	  insulin	  sensitivity.	  	  The	   prevailing	   hypothesis	   is	   that	   metformin	   activates	   AMPK	   by	   increasing	  ADP/AMP	  through	  inhibition	  of	  mitochondrial	  respiration,	  however,	  alternative	  models	  have	   been	   proposed.	   For	   example,	   it	   has	   been	   argued	   that	   the	   metabolic	   alterations	  induced	   by	   metformin	   in	   isolated	   skeletal	   muscle	   cells	   are	   not	   consistent	   with	   the	  interruption	  of	  mitochondrial	  energy	  supply;	  instead	  they	  better	  reflect	  direct	  inhibition	  of	  the	  enzyme	  AMP	  deaminase	  [27].	  This	  too	  would	  result	  in	  increased	  AMP	  levels	  and	  activation	  of	  AMPK.	  However	  the	  results	  of	  this	  study	  have	  been	  called	  into	  question	  due	  to	   the	   very	  high	   concentrations	   of	  metformin	  used	   [19].	   It	   has	   also	   been	   claimed	   that	  AMPK	   itself	   is	  a	  direct	   target	  of	  metformin.	  Specifically,	   low	  metformin	  concentrations	  can	  promote	  the	  formation	  of	  the	  AMPK	  αβγ	  heterotrimeric	  complex	  in	  hepatocytes	  and	  when	   the	   enzyme	   is	   assembled	   in	   vitro,	   leading	   to	   increased	   phosphorylation	   of	   the	  catalytic	  α	  subunit,	  although	  potential	  metformin	  binding	  sites	  have	  not	  been	  identified	  [28].	  However,	  this	  finding	  contradicts	  those	  obtained	  in	  previous	  studies	  that	  employed	  cell-­‐free	   assays	   to	   demonstrate	   that	   metformin	   is	   not	   a	   direct	   allosteric	   activator	   of	  AMPK	  [20,	  29].	  Thus,	  inhibition	  of	  the	  respiratory	  chain	  and	  the	  accompanying	  elevation	  in	  AMP	  levels	  remains	  the	  most	  plausible	  mechanism	  to	  explain	  the	  activation	  of	  AMPK	  by	  metformin.	  	  
AMPK-­‐independent	  mechanisms	  With	  doubts	  being	  cast	  on	  AMPK’s	  status	  as	   the	  central	  mediator	  of	  metformin	  action,	  several	   AMPK-­‐independent	   mechanisms	   have	   been	   proposed.	   One	   alternative	  explanation	   is	   that	   the	   associated	   change	   in	   cellular	   energy	   charge	  directly	  modulates	  glucose	   output.	   Gluconeogenesis	   is	   energetically	   demanding	   process	   requiring	   6	   ATP	  equivalents	  for	  every	  molecule	  of	  glucose	  synthesised	  [30].	  Since	  metformin	  treatment	  causes	   ATP	   levels	   to	   fall,	   hepatocytes	   must	   respond	   by	   reducing	   glucose	   production	  accordingly.	   Indeed,	   Foretz	   et	   al.	   demonstrated	   that	   reduction	   of	   ATP	   content	   and	  inhibition	  of	  glucose	  production	  were	  strongly	  correlated	  in	  mouse	  primary	  hepatocytes	  incubated	  with	  metformin,	   underscoring	   the	   close	   link	   between	   hepatic	   energy	   status	  and	   glucose	   output	   [24].	   Additionally,	   metformin-­‐induced	   changes	   in	   cellular	   energy	  status	  may	  suppress	  gluconeogenesis	  via	  the	  allosteric	   inhibition	  of	  essential	  enzymes.	  For	  example,	  AMP	  is	  capable	  of	  synergising	  with	  fructose	  2,6-­‐bisphosphate	  to	  inhibit	  the	  key	  gluconeogenic	  enzyme	  fructose	  1,6-­‐bisphosphatase	  [31].	  	   The	   notion	   that	   the	   molecular	   mechanism	   of	   metformin	   is	   independent	   of	  transcriptional	  alterations	   is	   supported	  by	  gene	  expression	  studies.	  Forced	  expression	  of	  PGC-­‐1α,	  a	  master	  co-­‐activator	  of	  gluconeogenic	  genes,	  does	  not	  negate	  the	  metformin-­‐induced	   suppression	   of	   glucose	   production	   in	   primary	   hepatocytes	   [24].	   Moreover,	  additional	   studies	   have	   found	   a	   lack	   of	   correlation	   between	   gluconeogenic	   gene	  expression	  and	  hepatic	  glucose	  output	  both	  in	  mouse	  models	  [32]	  and	  in	  patients	  with	  T2D	   [33].	   Taken	   together,	   these	   findings	   imply	   that	   inhibition	   of	   gluconeogenic	   gene	  expression	   is	   not	   the	   central	   determinant	   of	   metformin’s	   clinical	   effects;	   instead	   the	  changes	   in	   cellular	   energy	   charge	   and	   the	   associated	   reduction	   in	   gluconeogenic	   flux	  may	  be	  responsible.	  	   An	  alternative	  AMPK-­‐independent	  mechanism	  of	  metformin	  action	  has	  recently	  been	  put	   forward	  by	  Miller	  et	  al.	   that	   involves	   antagonism	  of	   glucagon	   signalling.	  The	  results	   of	   a	   series	   of	   in	   vivo	   and	   in	   vitro	   experiments	   on	  mouse	   primary	   hepatocytes	  have	  shown	  that	  metformin	  and	  the	  related	  biguanide	  phenformin	  block	  the	  glucagon-­‐induced	  activation	  of	   adenylate	   cyclase	   leading	   to	   a	   reduction	   in	   cAMP	  synthesis	   [34].	  This	   in	   turn	   lowers	   protein	   kinase	   A	   (PKA)	   activity,	   abrogating	   phosphorylation	   of	  critical	   substrates	   that	   enhance	   gluconeogenesis	   such	   as	   6-­‐phosphofructo-­‐2-­‐kinase/fructose-­‐2,6-­‐biphosphatase	  1,	  CREB-­‐1	  and	  inositol	  trisphosphate	  receptor.	  It	  has	  been	  proposed	  that	  the	  metformin-­‐associated	  rise	  in	  cellular	  AMP	  levels	  is	  responsible	  for	  the	  inhibition	  of	  adenylate	  cyclase,	  possibly	  due	  to	  the	  direct	  binding	  AMP’s	  adenine	  moiety	  to	  an	  inhibitory	  ‘P-­‐site’	  [34].	  	   While	   this	   finding	   is	   undoubtedly	   significant,	   an	   important	   caveat	   has	   been	  raised.	   If	   antagonism	   of	   glucagon	   signalling	   was	   the	   major	   mechanism	   of	   metformin	  action,	   it	   would	   be	   reasonable	   to	   assume	   that	   the	   use	   of	   this	   drug	   may	   lead	   to	  hypoglycaemic	   episodes	   as	   seen	   in	   glucagon	   receptor	   knock-­‐out	   mice	   [35].	   However,	  one	  of	  the	  main	  advantages	  of	  metformin	  treatment	  is	  that	  hypoglycaemia	  is	  rare.	  This	  implies	   that	   either	   the	   suppression	   of	   glucagon	   signalling	   is	   incomplete	   in	   humans	   or	  that	  compensatory	  mechanisms	  are	  at	  work	  [36].	  It	   should	  be	  noted	   that	   the	   studies	  on	  which	   these	  AMPK-­‐independent	  models	  are	   based	   have	   received	   criticism	   for	   using	   concentrations	   of	   metformin	   that	   are	  considered	   higher	   than	   the	  maximally	   achievable	   therapeutic	   concentrations	   found	   in	  diabetic	   patients	   [37].	   Metformin	   is	   administered	   orally	   and	   has	   a	   maximum	  recommended	  dose	  of	  2.5	  g	  per	  day	  in	  humans.	  It	  has	  been	  demonstrated	  that	  the	  peak	  plasma	   concentration	   reaches	   approximately	   3	   µg/ml	   (equivalent	   to	   18	   µM)	   in	  individuals	  who	  have	  taken	  a	  single	  dose	  of	  1.5	  g	  [38].	  However,	  evidence	  from	  animal	  studies	   show	   that	   the	   concentration	   of	   metformin	   in	   the	   hepatic	   portal	   vein	   is	  considerably	  higher	  than	  that	  of	  the	  systemic	  plasma	  [39].	  Cao	  et	  al.	  tested	  the	  effect	  of	  metformin	  at	  low	  concentrations	  (≤	  80	  µM)	  in	  mouse	  primary	  hepatocytes.	  Under	  these	  conditions,	  metformin	   suppressed	   gluconeogenic	   gene	   expression	   and	  hepatic	   glucose	  production	  via	  AMPK,	  yet	  no	  effect	  was	  observed	  on	  ATP	   levels	  or	   the	  AMP/ATP	  ratio	  
implying	   that	   complex	   I	   is	   not	   inhibited	   [40].	   However,	   it	   is	   unclear	   how	   metformin	  could	  activate	  AMPK	  without	  inducing	  a	  change	  in	  cellular	  energy	  charge.	  Furthermore,	  it	   has	   been	   shown	   previously	   that	   even	   if	   changes	   in	   the	   AMP/ATP	   ratio	   are	  undetectable,	   the	  activation	  of	  AMPK	  by	  metformin	   is	   still	  dependent	  on	  AMP	  binding	  [41].	   Although	   both	   Foretz	   et	   al.	   and	  Miller	   et	   al.	   have	   used	   high	   concentrations	   to	  provide	  evidence	  for	  an	  AMPK-­‐independent	  mechanism	  of	  metformin	  action,	  it	  does	  not	  necessarily	  mean	  that	  their	  findings	  should	  be	  dismissed	  as	  clinically	  irrelevant.	  	  For	  in	  
vivo	  experiments	  involving	  rodents	  it	  is	  common	  to	  administer	  metformin	  at	  daily	  doses	  between	  250	  –	  350	  mg/kg.	  These	  values	  are	  obtained	  using	  a	  well-­‐established	  method	  for	  converting	  doses	  between	  species	  based	  on	  normalisation	  to	  body	  surface	  area	  [42].	  According	  to	  this	  formula,	  a	  standard	  therapeutic	  dose	  of	  20	  mg/kg	  in	  an	  adult	  human	  (60	   kg)	   is	   approximately	   equivalent	   to	   a	   250	  mg/kg	   dose	   in	   a	  mouse.	  Moreover,	   it	   is	  known	  that	  relatively	  high	  concentrations	  are	  required	  in	  order	  for	  the	  drug	  to	  exert	  its	  therapeutic	  effect	  in	  diabetic	  rodents	  [24,	  43].	  Additionally,	  metformin	  has	  been	  shown	  to	  accumulate	  at	  very	  high	  concentrations	  in	  several	  tissues.	  In	  mice,	  a	  dose	  of	  50	  mg/kg	  can	   lead	   to	   concentrations	   greater	   than	   250	   µM	   in	   the	   liver	   and	   those	   within	   the	  millimolar	  range	  in	  the	  small	  intestine	  [39].	  Thus	  the	  use	  of	  concentrations	  that	  exceed	  those	  typically	   found	   in	   the	  plasma	  or	  portal	  vein	  can	  be	   justifiable	   for	   in	  vitro	   studies	  involving	   primary	   hepatocytes.	   Furthermore,	   it	   is	   known	   that	   the	   biological	   effects	   of	  metformin	  are	  time-­‐dependent	  as	  well	  as	  concentration-­‐dependent	  [20];	  a	  property	  that	  likely	  reflects	  its	  capacity	  to	  accumulate	  within	  the	  mitochondrial	  matrix.	  Therefore	  it	  is	  possible	   that	   effects	   observed	   at	   high	   concentrations	   may	   also	   occur	   at	   lower	  concentrations	  following	  more	  long-­‐term	  exposure	  to	  metformin.	  It	  is	  also	  worth	  mentioning	  that	  studies	  that	  have	  used	  hepatic	  AMPK	  knockout	  models	   to	   support	   an	   AMPK-­‐independent	   mechanism	   of	   metformin	   action	   should	   be	  reviewed	  in	  light	  of	  new	  evidence	  that	  demonstrates	  the	  importance	  of	  intestinal	  AMPK	  in	  mediating	  metformin	  action.	  Although	   the	   liver	   is	   considered	   to	  be	   the	  main	   site	  of	  metformin	  action,	  it	  has	  recently	  been	  demonstrated	  that	  activation	  of	  intestinal	  AMPK	  contributes	   to	   the	   acute	   glucose-­‐lowering	   effects	   of	  metformin.	  A	   study	  performed	  on	  insulin-­‐resistant	   rats	  has	  uncovered	   the	   involvement	  of	  a	  gut-­‐brain-­‐liver	  axis	  whereby	  metformin	   triggers	  a	  duodenal	  AMPK-­‐glucagon-­‐like	  peptide-­‐1	   receptor-­‐Pka-­‐dependent	  neuronal	   signalling	   pathway	   to	   reduce	   hepatic	   glucose	   production	   [44].	   This	   study	  alludes	   to	   the	   possibility	   that	   the	   activation	   of	   AMPK	   in	   organs	   usually	   under	   the	  presence	   of	   elevated	   concentrations	   of	   the	  drug	   (in	   the	  milimolar	   range)	   can	   regulate	  from	  a	  distance	  the	  metabolism	  of	  tissues	  directly	  responsible	  for	  glucose	  production..	  A	   novel	   mechanism	   of	   metformin	   action	   has	   been	   recently	   revealed	   that	   is	  independent	  of	  both	  AMPK	  activation	  and	  cellular	  energy	  charge.	  Specifically,	  metformin	  has	   been	   found	   to	   inhibit	   the	   glycerophosphate	   shuttle	   enzyme	   mitochondrial	  glycerophosphate	   dehydrogenase	   (mGPD).	   This	   prevents	   glycerol	   from	   being	   directly	  used	   as	   a	   gluconeogenic	   substrate.	   It	   also	   leads	   to	   an	   increase	   in	   the	   cytosolic	   redox	  state	  which	  makes	   the	   conversion	   of	   lactate	   to	   pyruvate	   unfavourable	   and	   thus	   limits	  the	   contribution	   of	   lactate	   to	   gluconeogenic	   flux	   [45].	   In	   addition	   to	   revealing	   a	   new	  therapeutic	   target,	   this	  study	  helps	  to	   further	  underscore	  metformin’s	  status	  as	  a	  non-­‐specific	  drug	  that	  is	  capable	  of	  interfering	  with	  multiple	  molecular	  targets	  to	  bring	  about	  the	  disruption	  of	  gluconeogenesis.	  	  
Metformin	  and	  Cardiovascular	  Disease	  Cardiovascular	   disease	   (CVD)	   encompasses	   diseases	   of	   the	   heart	   and	   circulation.	  According	  to	  the	  British	  Heart	  Foundation,	  CVD	  accounts	  for	  more	  than	  a	  quarter	  of	  all	  deaths	  in	  the	  UK	  with	  an	  estimated	  cost	  per	  year	  of	  £19	  billion.	  The	  greatest	  risk	  factor	  of	   CVD	   is	   T2D.	   There	   is	   evidence	   that	  metformin	   can	   offer	   protection	   against	   CVD	   in	  diabetic	   patients.	   This	   is	   especially	   pertinent	   given	   that	   CVD	   is	   the	   leading	   cause	   of	  
mortality	  within	   this	   population	   [46].	   In	   the	   landmark	  UK	  Prospective	  Diabetes	   Study	  (UKPDS),	   it	   was	   reported	   that	   metformin	   treatment	   lowered	   the	   risk	   of	   myocardial	  infarction	  by	  39%	  when	  compared	  to	  traditional	  treatments	  over	  a	  period	  of	  ten	  years	  [47].	   Subsequent	   trials	   have	   supported	   a	   beneficial	   role	   for	   metformin	   in	   protecting	  against	   the	   cardiovascular	   complications	  of	  diabetes,	   including	  a	   ten-­‐year	   follow-­‐up	  of	  the	  original	  UKPDS	  trial	  [48-­‐50].	  Whilst	  improvements	  in	  glucose	  and	  lipid	  metabolism	  may	   contribute	   to	   some	   of	   the	   positive	   effects	   conferred	   by	   metformin,	   numerous	  alternative	  mechanisms	  invoking	  direct	  action	  of	  the	  drug	  on	  the	  cardiovascular	  system	  have	  also	  been	  discovered.	  The	   results	   of	   multiple	   studies	   suggest	   that	   metformin	   can	   protect	   against	  atherosclerosis	   by	   promoting	   endothelial	   integrity	   and	   preventing	   the	   formation	   of	  plaques.	   For	   example,	   it	   has	   been	   reported	   that	   the	   activation	   of	  AMPK	  by	  metformin	  limits	   endothelial	   cell	   damage	   caused	   by	   oxidative	   stress	   under	   hyperglycaemic	  conditions.	  This	  occurs	  via	  inhibition	  of	  the	  protein	  kinase	  C-­‐NAD(P)H	  oxidase	  pathway	  [51].	  The	  resulting	  reduction	  in	  cytosolic	  reactive	  oxygen	  species	  (ROS)	  generation	  halts	  the	   initiation	   of	   a	   positive	   feedback	   loop	   involving	  mitochondrial	   ROS	   generation	   and	  mitochondrial	  fission,	  which	  in	  turn	  prevents	  the	  triggering	  of	  endothelial	  apoptosis	  by	  the	  resulting	  loss	  of	  mitochondrial	  membrane	  potential	  [52].	  	   Metformin	   has	   also	   been	   observed	   to	   exhibit	   anti-­‐thrombotic	   properties	   in	  insulin-­‐resistant	   models.	   Specifically,	   metformin	   counteracts	   the	   stimulatory	   effect	   of	  hyperinsulinaemia	   on	   the	   production	   of	   plasminogen	   activator	   inhibitor	   1	   (PAI-­‐1),	   a	  negative	  regulator	  of	   fibrinolysis	   implicated	   in	  blood	  clot	   formation	  [53].	   It	   is	  believed	  that	  that	  this	  is	  not	  mediated	  by	  the	  improvement	  in	  insulin	  sensitivity	  associated	  with	  metformin	  but	  rather	  by	  the	  direct	  inhibition	  of	  PAI-­‐1	  gene	  expression	  [54].	  Moreover,	  metformin	   treatment	  has	  been	  observed	  to	  significantly	  reduce	  platelet	  aggregation	   in	  patients	   with	   insulin-­‐dependent	   diabetes	   [55].	   This	   finding	   may	   be	   explained	   by	   the	  results	  of	   a	   subsequent	   study	   in	  which	   it	  was	  discovered	   that	  metformin	   can	  enhance	  Ser1179	   phosphorylation	   of	   endothelial	   nitric	   oxide	   synthase	   in	   an	   AMPK-­‐dependent	  manner	  leading	  to	  an	  increase	  in	  nitric	  oxide	  (NO)	  bioactivity	  in	  the	  aortas	  of	  C57BL/6	  mice	  [56].	  NO	  plays	  a	  crucial	  role	   in	  maintaining	  vascular	  homeostasis	  by	  carrying	  out	  multiple	   functions,	   including	   inhibition	   of	   platelet	   aggregation,	   and	   therefore	   helps	   to	  protect	  against	  the	  development	  of	  coronary	  artery	  disease.	  	   In	  addition	  to	  its	  endothelial	  actions,	  metformin	  affects	  cardiomyocyte	  function	  and	   has	   been	   associated	   with	   improvements	   in	   diabetic	   cardiomyopathy	   in	   rodent	  models.	  This	  distinct	  condition	  is	  a	  major	  cause	  of	  heart	  failure	  and	  is	  characterised	  by	  ventricular	  dysfunction	  independent	  of	  coronary	  artery	  disease	  and	  hypertension	  [57].	  It	   was	   previously	   suggested	   that	   metformin	   may	   correct	   abnormalities	   in	   myocyte	  relaxation	   via	   tyrosine	   kinase-­‐dependent	   alterations	   in	   calcium	   handling	   [58].	   More	  recent	   studies	   have	   linked	   improvements	   in	   diabetic	   cardiomyopathy	   to	   AMPK-­‐mediated	   upregulation	   of	   autophagy	   [59,	   60].	   Cardiac	   autophagy	   is	   an	   important	  homeostatic	  mechanism	  known	  to	  be	  supressed	  in	  diabetic	  cardiomyopathy.	  It	  has	  been	  demonstrated	   that	   metformin-­‐activated	   AMPK	   protects	   cardiomyocytes	   by	   disrupting	  the	  Beclin1-­‐Bcl-­‐2	  (B-­‐cell	  lymphoma	  2)	  complex	  and	  inducing	  a	  switch	  from	  apoptotic	  to	  autophagic	   machinery.	   Importantly,	   this	   restoration	   of	   autophagy	   improves	   cardiac	  structure	  and	  function	  in	  diabetic	  mice	  [59].	  There	  is	  also	  evidence	  to	  suggest	  that	  metformin	  exerts	  a	  cardioprotective	  effect	  against	   ischemia	   reperfusion	   injury	   following	  myocardial	   infarction.	  Administration	  of	  metformin	   during	   the	   first	   15	   minutes	   of	   reperfusion	   has	   been	   shown	   to	   reduce	  myocardial	  infarct	  size	  in	  hearts	  isolated	  from	  both	  diabetic	  and	  non-­‐diabetic	  rats	  [61].	  This	  was	  attributed	  to	  the	  activation	  of	  the	  protein	  kinase	  B	  (Akt)/ phosphatidylinositol-­‐4,5-­‐bisphosphate	  3-­‐kinase	  (PI3K)	  signalling	  pathway	  by	  metformin,	  which	  prevents	  the	  opening	  of	  the	  mitochondrial	  permeability	  transition	  pore	  (mPTP)	  –	  a	  critical	  trigger	  of	  cell	  death	  during	  reperfusion.	  It	  has	  since	  been	  shown	  that	  AMPK	  activation	  also	  inhibits	  mPTP	   opening	   at	   reperfusion	   [62].	   Moreover,	   an	   AMPK-­‐mediated	   increase	   in	   eNOS	  
activity	   has	   also	   been	   proposed	   to	   explain	   the	   positive	   effect	   of	   acute	   metformin	  treatment	  on	  infarct	  size	  [63].	  It	  is	  interesting	  to	  note	  that	  a	  new	  small-­‐molecule	  AMPK	  activator	   (A-­‐76922)	  has	  been	   shown	   to	   act	   synergistically	  with	  metformin	   to	   enhance	  the	   cardioprotective	  effects	  of	  AMPK	  activation	  and	   therefore	  may	  have	  useful	   clinical	  applications	  during	  an	  ischemia	  reperfusion	  episode	  [64].	  The	  effect	  of	  chronic	  metformin	  treatment	  on	  ischemia	  reperfusion	  injury	  has	  also	  been	  investigated,	   although	   to	   a	   lesser	   extent.	   One	   study	   has	   shown	   that	   administration	   of	  metformin	  over	  a	  4-­‐week	  period	  reduced	  infarct	  size	  in	  isolated	  rat	  hearts	  regardless	  of	  diabetes	   status	   [65].	   The	   cardioprotection	   observed	   in	   diabetic	   hearts	  was	   associated	  with	   improved	   mitochondrial	   organisation,	   possibly	   related	   to	   increased	   AMPK	  activation	   and	  PGC-­‐1α	   expression.	   Furthermore,	   long-­‐term	  metformin	   treatment	  post-­‐myocardial	   infarction	  may	   also	   have	   a	   positive	   impact.	   It	   has	   been	  demonstrated	   that	  rats	   treated	   with	   metformin	   for	   12	   weeks	   following	   myocardial	   infarction	   exhibited	  enhanced	   AMPK	   activation	   and	   improved	   cardiac	   remodelling,	   suggesting	   that	  metformin	  could	  help	  attenuate	  the	  development	  of	  heart	  failure	  in	  such	  a	  scenario	  [66].	  	  Ultimately,	   the	   evidence	   suggests	   that	  metformin	   exerts	   varied	   positive	   effects	   on	   the	  cardiovascular	  system,	  particularly	  in	  diabetic	  models.	  Several	  randomised	  control	  trials	  in	   non-­‐diabetic	   individuals	   are	   currently	   underway	   and	   data	   from	   these	   will	   help	   to	  establish	  whether	   or	   not	  metformin	   can	   improve	   cardiovascular	   outcomes	   in	   a	  wider	  section	  of	  society.	  	  
Metformin	  and	  Cancer	  Cancer	   is	  a	   leading	  cause	  of	  morbidity	  and	  mortality	  worldwide.	  A	  recent	   lifetime	  risk	  analysis	  of	  the	  British	  population	  found	  that	  over	  50%	  of	  adults	  below	  the	  age	  of	  65	  will	  be	  diagnosed	  with	  the	  disease	  at	  some	  point	  in	  their	  life	  [67].	  Sobering	  projections	  like	  this	   have	   stimulated	   an	   enormous	   amount	   of	   investment	   into	   cancer	   research	   and	  rational	  drug	  design.	  Despite	  our	  best	  efforts,	  only	  5%	  of	  oncology	  drugs	  entering	  phase	  I	  trials	  eventually	  receive	  approval	  and	  it	  has	  been	  argued	  that	  so	  far,	  targeted	  therapies	  have	   provided	   only	   modest	   survival	   benefits	   [68].	   Metformin	   garnered	   considerable	  interest	   within	   the	   field	   of	   oncology	   in	   2005	   following	   the	   publication	   of	   an	  epidemiological	   report	   highlighting	   a	   link	   between	  metformin	   treatment	   and	   reduced	  cancer	  risk	  in	  diabetic	  patients	  [69].	  This	  finding	  has	  stimulated	  a	  great	  deal	  of	  further	  research,	   and	   numerous	   observational	   studies	   have	   supported	   a	   protective	   role	   for	  metformin	   against	   a	   variety	   of	   cancer	   types	   including	   liver,	   colorectal,	   pancreas,	  stomach	  and	  oesophagus	  cancer	  in	  diabetics	  [70].	  However,	  it	  is	  important	  to	  note	  that	  such	  studies	  are	  prone	  to	  bias	  and	  confounding	  factors	  and	  contrastingly,	  meta-­‐analyses	  of	   randomised	   controlled	   trials	   do	   not	   appear	   to	   demonstrate	   a	   significant	   effect	   of	  metformin	  on	  cancer	  outcomes	  [70-­‐72].	  Furthermore,	  it	  is	  not	  clear	  whether	  or	  not	  any	  positive	   results	   could	   be	   extrapolated	   to	   non-­‐diabetic	   individuals.	   Nevertheless,	  increasing	   importance	   is	  being	  placed	  on	   the	  role	  of	  altered	  metabolism	   in	  cancer	  and	  the	   ability	   of	   metformin	   to	   interact	   with	   several	   metabolic	   pathways	   suggests	   that	   it	  could	  be	  effective	  at	  preventing	  the	  development	  and	  progression	  of	  this	  disease.	  	  It	   is	  possible	  that	  the	  systemic	  effects	  of	  metformin	  could	  be	  protective	  against	  cancer.	   Both	   experimental	   and	   epidemiological	   evidence	   suggests	   that	   insulin	   and	  insulin-­‐like	   growth	   factor	   1	   (IGF-­‐1)	   can	   promote	   tumourigenesis	   by	   stimulating	   the	  proliferation	  of	  epithelial	  cells	  [73].	  Metformin	  may	  prevent	  such	  neoplastic	  activity	  by	  reducing	   hyperinsulinaemia	   and	   lowering	   levels	   of	   these	   signalling	   molecules.	  Metformin	   can	   also	   modify	   inflammatory	   processes	   known	   to	   play	   a	   role	   in	   cancer	  progression.	  For	  example,	  it	  has	  been	  reported	  that	  metformin	  blocks	  the	  activity	  of	  the	  transcription	   factor	  nuclear	   factor-­‐κB	   (NF-­‐κB)	   resulting	   in	  decreased	  secretion	  of	  pro-­‐inflammatory	  cytokines	  by	  senescent	  cells	  [74].	  This	  mechanism	  may	  also	  contribute	  to	  the	   anti-­‐ageing	   properties	   of	   the	   drug	   as	   outlined	   below.	   Additionally,	  metformin	   has	  been	  found	  to	  enhance	  the	  immune	  response	  to	  cancer	  cells.	  A	  recent	  study	  performed	  
in	   a	   mouse	   model	   demonstrated	   that	   metformin	   protects	   CD8+	   tumour-­‐infiltrating	  lymphocytes	   from	  apoptosis	  and	   functional	  exhaustion	   [75].	  Encouragingly,	   it	  has	  also	  been	   shown	   that	  metformin	  was	  able	   to	   improve	   the	  efficacy	  of	   an	  experimental	   anti-­‐cancer	  vaccine	  by	  promoting	  the	  survival	  of	  memory	  T	  cells	  [76].	  There	   are	   several	   lines	   of	   evidence	   that	   suggest	   metformin	   can	   exert	   cancer	  preventative	   effects	   in	   a	   cell-­‐autonomous	  manner.	   The	   ability	   of	  metformin	   to	   inhibit	  complex	   I	   and	   disrupt	   oxidative	   phosphorylation	   has	   recently	   been	   highlighted	   as	   an	  important	  requirement	  for	  tumourigenesis	  inhibition.	  Metabolomic	  analysis	  of	  a	  breast	  epithelial	   cell	   line	   undergoing	   neoplastic	   transformation	   has	   revealed	   that	  metformin	  decreases	   tricarboxylic	   acid	   cycle	   intermediates	   which	   implies	   impaired	   complex	   I	  activity	   and	   therefore	   reinforces	   the	   notion	   that	   this	   enzyme	   is	   a	   key	   target	   [77].	  Crucially,	   it	  has	  been	  demonstrated	   that	   the	  anti-­‐tumorigenic	  effect	  of	  both	  metformin	  and	   phenformin	   is	   reversed	   in	   cancer	   cells	   that	   are	   forced	   to	   express	   yeast	   NADH	  dehydrogenase	  NDI1	  which	  enables	  complex	  I	  function	  to	  be	  bypassed	  [78,	  79].	  	  
AMPK-­‐dependent	  mechanism	  The	  activation	  of	  the	  LKB1/AMPK	  pathway	  may	  also	  significantly	  contribute	  to	  the	  anti-­‐cancer	   effects	   of	  metformin.	   The	  AMPK	  up-­‐stream	   activator	   LKB1	   is	   a	   known	   tumour	  suppressor	  and	  mutations	  in	  this	  gene	  are	  associated	  with	  Peutz-­‐Jeghers	  syndrome,	  an	  inherited	   cancer-­‐predisposing	   disorder,	   as	   well	   as	   several	   sporadic	   cancers	   [80].	  Additionally,	   it	   has	   been	   demonstrated	   that	   the	   protective	   effect	   of	   metformin	   is	  attenuated	   by	   pharmacological	   inhibition	   of	   AMPK	   and	   in	   AMPK-­‐knockdown	   models	  [81-­‐83].	  A	  major	  consequence	  of	  AMPK	  activation	  is	   inhibition	  of	  mammalian	  target	  of	  rapamycin	   (mTOR)	   signalling,	   a	   nutrient-­‐sensitive	   regulator	   of	   protein	   synthesis,	   cell	  growth	   and	   proliferation.	   This	   is	   achieved	   via	   directly	   phosphorylation	   of	   Ser1345	  and	  Thr1227	  on	   the	   tumour	  suppressor	  protein	   tuberous	  sclerosis	  2	   (TSC2),	  which	   forms	  an	  mTOR	   Complex	   1	   (mTORC1)-­‐inhibitory	   complex	   with	   TSC1[84].	   Alternatively,	   AMPK	  can	  prevent	  mTORC1	  activation	  by	  phosphorylating	  its	  binding	  partner	  Raptor	  [85].	  	  	   AMPK	  activation	  has	  been	  associated	  with	  suppression	  of	  the	  Warburg	  effect	  –	  a	  metabolic	  phenotype	  adopted	  by	  cancer	  cells	  characterised	  by	  a	  preference	  for	  aerobic	  glycolysis	   over	   oxidative	   phosphorylation	   [86].	   This	   transformation	   is	   facilitated	   by	  hypoxia-­‐inducible	   factor	   1α,	   a	   transcription	   factor	   that	   upregulates	   glycolytic	   gene	  expression	   partly	   in	   response	   to	   mTORC1	   signalling.	   A	   related	   classic	   metabolomic	  hallmark	  of	   cancer	   is	   increased	  de	  novo	   fatty	   acid	   synthesis	   and	   elevated	   levels	   of	   the	  key	  lipogenic	  enzyme	  fatty	  acid	  synthase	  (FAS)	  has	  been	  described	  in	  a	  wide	  variety	  of	  human	  cancers	  [87].	  It	  has	  been	  demonstrated	  that	  the	  activation	  of	  AMPK	  reduced	  FAS	  expression	   in	   prostate	   cancer	   cells	   and	   was	   able	   to	   diminish	   their	   viability	   [88].	  Similarly,	   experimental	   work	   conducted	   in	   a	   mouse	   model	   of	   colon	   carcinoma	   has	  shown	   that	   metformin	   down	   regulates	   the	   expression	   of	   FAS	   and	   can	   counteract	   the	  stimulatory	  effect	  of	  a	  high-­‐energy	  diet	  on	  tumour	  growth	  [89].	  These	  findings	  suggest	  that	  metformin	  may	  exert	   its	  anti-­‐cancer	  effects	  by	   inducing	  alterations	   in	  glucose	  and	  lipid	  metabolism	  that	  ultimately	  deprive	  cancer	  cells	  of	  vital	  growth	  substrates.	  	   Recent	  reports	  reveal	  that	  metformin	  can	  act	  as	  an	  anti-­‐folate	  drug	  [90,	  91]	  and	  show	   that	  metformin	   impairs	   the	   folate	   cycle	   similarly	   to	   the	   action	   of	   the	   antifolate	  class	  of	  chemotherapy	  drugs.	  The	  folate	  or	  one-­‐carbon	  cycle	  is	  a	  major	  regulator	  of	  cell	  metabolism	  and	  an	  integrator	  of	  nutrient	  status	  [92].	  It	  assimilates	  inputs	  in	  the	  form	  of	  glucose	  and	  amino	  acids	  that	  are	  processed	  through	  chemical	  reactions	  and	  transformed	  for	  diverse	  biological	  functions.	  These	  include	  cellular	  biosynthesis,	  regulation	  of	  redox	  status,	   regulations	   of	   epigenetics	   through	   nucleic	   acid	   and	   protein	   methylation,	   and	  genome	  maintenance	  through	  the	  regulation	  of	  nucleotide	  pools.	  For	  example,	  the	  folate	  cycle	  regulates	  de	  novo	  synthesis	  of	  nucleotides	  required	  for	  DNA	  repair	  and	  replication	  and	  the	  production	  of	   the	  universal	  methyl	  donor	  S-­‐adenosylmethionine,	   involved	   in	  a	  number	   of	  methylation	   reactions	   such	   as	  DNA	  methylation	   [93].	   Chemotherapy	   drugs	  such	  as	  methotrexate,	  aminopterine	  and	  azaserine	  block	   folate	  metabolism	  and	   impair	  
de	  novo	   synthesis	   of	   both	   thymidylate	   and	  purine	  nucleotides.	  We	  have	  demonstrated	  that	   metformin	   disrupts	   folate	   and	   methionine	   metabolism	   in	   E.	   coli	   [90].	   Similarly,	  metformin	   treatment	   impairs	   folate	   metabolism	   in	   several	   breast	   cancer	   cells	   with	  concomitant	   reduction	   in	   glutathione	   and	   tryptophan	   metabolites	   [91].	   Thymidine	  serves	  as	  a	  thymidylate	  precursor	  in	  the	  pyrimidine	  salvage	  pathway	  and	  hypoxanthine	  is	   an	   inosine	   monophosphate	   precursor	   in	   the	   purine	   salvage	   pathway	   in	   de	   novo	  synthesis.	   In	   fact,	   hypoxanthine	   and	   thymidine	   supplementation	   rescues	   the	   cytotoxic	  effects	   of	   metformin	   on	   cancer	   cells	   independently	   of	   LKB1	   but	   requiring	   the	   AMPK	  kinase	  ataxia	  telangiectasia	  mutated	  kinase	  (ATM)/APMK	  axis	  [91].	  In	  a	  study	  by	  Janzer	  
et	   al.,	   metformin	   induced	   a	   cancer	   stem	   cell-­‐specific	   depletion	   of	   nucleotide	  triphosphates	  [77].	  	   Aside	  from	  these	  metabolic	  modifications,	  there	  is	  evidence	  that	  the	  activation	  of	  AMPK	  by	  metformin	  may	  help	   to	   regulate	   the	   cell	   cycle	   via	   interactions	  with	   classical	  oncogenes	   and	   tumour	   suppressors.	   For	   example,	   it	   has	   been	   demonstrated	   that	  metformin	  downregulates	   c-­‐MYC	   in	   an	  AMPK-­‐dependent	  manner	   in	  breast	   cancer	   cell	  lines	  [94].	  This	  is	  mediated	  by	  increased	  expression	  of	  miR-­‐33a,	  a	  microRNA	  that	  binds	  to	  the	  3’-­‐UTR	  region	  of	  c-­‐MYC,	  which	  in	  turn	  results	  from	  the	  upregulation	  of	  the	  RNAse	  III	   enzyme	   Dicer	   in	   response	   to	   metformin	   treatment.	   The	   modulation	   of	   Dicer	   by	  metformin	   is	   especially	   relevant	   given	   that	   low	   levels	   of	   this	   enzyme	   have	   been	  associated	  with	   poor	   prognosis	   in	   ovarian,	   breast	   and	   lung	   cancer	   [95-­‐97].	   AMPK	  has	  also	  been	  shown	  to	  target	  p53.	  One	  study	  reported	  that	  AMPK	  initiates	  cell-­‐cycle	  arrest	  by	  phosphorylating	  Ser15	  of	  p53	  [98],	  although	  it	  has	  been	  argued	  that	  this	  event	  is	  not	  sufficient	  for	  p53	  activation.	  Findings	  from	  a	  subsequent	  study	  have	  revealed	  that	  AMPK	  phosphorylates	  the	  p53	  regulator	  murine	  double	  minute	  X	  (MDMX)	  at	  Ser342	  leading	  to	  its	   increased	  association	  with	  14-­‐3-­‐3	  proteins.	  This	  suppresses	  p53	  ubiquitylation	  and	  enhances	  p53	  stability	  and	  activation	  [99].	  	  	   Whilst	   it	   is	   apparent	   that	   AMPK	   activation	   may	   protect	   against	   cancer	   via	  multiple	  mechanisms,	  it	   is	  also	  understood	  that	  during	  later	  stages	  of	  development	  the	  activation	  of	  AMPK	  may	  actually	  promote	   the	  survival	  of	   tumour	  cells.	  This	   is	  because	  AMPK	   enables	   the	   cells	   to	   adapt	   to	   metabolic	   stress	   imposed	   by	   the	   solid	   tumour	  microenvironment.	  Support	  for	  this	  hypothesis	  comes	  from	  a	  study	  demonstrating	  that	  the	   restoration	   of	   activated	   AMPK	   in	   LKB1-­‐deficient	   lung	   adenocarcinoma	   cells	  conferred	  protection	  against	  glucose-­‐starvation-­‐induced	  cell	  death	  [100].	  This	  suggests	  that	  the	  use	  of	  AMPK	  activators	  such	  as	  metformin	  may	  be	  harmful	  in	  some	  situations.	  Conversely,	  metformin	  and	  other	  compounds	  capable	  of	  inducing	  metabolic	  stress	  may	  be	  particularly	  effective	  against	  tumours	  lacking	  a	  functional	  LKB1-­‐AMPK	  axis.	  Indeed,	  it	  has	  been	  shown	  that	  in	  a	  transgenic	  mouse	  model	  of	  lung	  cancer,	  phenformin	  selectively	  induces	   apoptosis	   in	   cells	   bearing	   LKB1	  mutations	   [101].	   This	   reflects	   the	   inability	   of	  these	   cells	   to	   respond	   appropriately	   to	   the	  decline	   in	  ATP	  production	   associated	  with	  complex	  I	  inhibition.	  	  	  
AMPK-­‐independent	  mechanism	  AMPK-­‐independent	   mechanisms	   to	   explain	   the	   anti-­‐cancer	   properties	   of	   metformin	  have	  also	  been	  described.	  For	  instance,	  metformin	  can	  protect	  against	  DNA	  damage	  and	  mutation	  by	  inhibiting	  ROS	  generation	  by	  complex	  I	  [102].	  Additionally,	  metformin	  can	  activate	   mTORC1	   in	   the	   absence	   of	   AMPK	   in	   a	   comparable	   way	   to	   amino	   acid	  withdrawal.	   It	   achieves	   this	   by	   inhibiting	   Rag	   GTPases,	   which	   are	   responsible	   for	  inducing	  the	  translocation	  of	  mTORC1	  to	  cellular	  compartments	  containing	  the	  mTORC1	  activator,	  Ras	  homolog	  enriched	   in	  brain	  (Rheb)	  [103].	  There	   is	  also	  evidence	  to	  show	  that	  the	  antiproliferative	  effect	  of	  metformin	  in	  a	  prostate	  cancer	  cell	   line	  is	  associated	  with	  AMPK-­‐independent	  inhibition	  of	  the	  critical	  cell	  cycle	  regulator	  Cyclin	  D1	  [104].	  It	  is	   thought	   that	   this	   is	   mediated	   by	   a	   p53-­‐dependent	   upregulation	   of	   REDD1	   [105].	  Furthermore,	   AMPK	   activation	   may	   be	   dispensable	   for	   the	   triggering	   of	   cell	   death	  pathways	   induced	   by	   metformin	   treatment.	   A	   study	   conducted	   on	   oesophageal	  
squamous	   cell	   carcinoma	   cells	   showed	   that	   metformin	   upregulates	   apoptosis	   and	  autophagy	   resulting	   in	   reduced	   tumour	   growth	   [106].	   This	   was	   attributed	   to	  inactivation	   of	   the	   Stat3/Bcl2	  pathway,	  which	  was	   only	  marginally	   reverted	  by	  AMPK	  knock-­‐down	   suggesting	   a	   limited	   contribution.	   Finally,	   it	   has	   been	   demonstrated	   that	  metformin	   impairs	   glucose	   uptake	   in	   a	   lung	   cancer	   cell	   model	   via	   direct	   allosteric	  inhibition	   of	   hexokinase-­‐II	   [107].	   Deprivation	   of	   this	   energy	   source	   leads	   to	  mitochondrial	   depolarisation	   and	   the	   subsequent	   triggering	   of	   apoptosis.	   Similar	  findings	  have	  also	  been	  observed	  in	  a	  breast	  cancer	  cell	  line	  [108].	  	  	  
Anti-­‐cancer	  polypharmacy	  therapy	  with	  metformin	  Although	   metformin	   has	   shown	   considerable	   promise	   as	   a	   stand-­‐alone	   cancer	  treatment,	  the	  effect	  of	  metformin	  in	  combination	  with	  conventional	  cytotoxic	  therapies	  has	  also	  been	  investigated.	  There	  is	  evidence	  that	  metformin	  improves	  the	  response	  of	  cancer	   cells	   to	   radiotherapy	   [109].	   Metformin	   has	   also	   been	   found	   to	   enhance	   the	  sensitivity	  of	  multiple	  cancer	  cell	   types	  to	  common	  chemotherapeutic	  agents	   including	  cisplatin,	  paclitaxel,	  carboplatin,	  and	  doxorubicin	  [110-­‐112].	  However	  it	  should	  be	  noted	  that	  metformin	   antagonises	   the	   cytotoxic	   effect	   of	   cisplatin	   in	   glioma,	   neuroblastoma,	  fibrosarcoma	  and	  leukemia	  cell	  lines,	  reportedly	  via	  AMPK-­‐independent	  upregulation	  of	  the	  Akt	  survival	  pathway	  [113].	  Metformin	  may	  be	  particularly	  effective	  when	  used	   in	  combination	   with	   small	   molecule	   kinase	   inhibitors	   that	   suppress	   glycolysis.	   In	  melanoma	   cells	   it	   has	   been	   demonstrated	   that	   the	   efficacy	   of	   BRAF	   protein	   kinase	  inhibitors	  is	  limited	  by	  the	  induction	  of	  compensatory	  oxidative	  phosphorylation	  [114].	  Accordingly,	  several	  inhibitors	  of	  oxidative	  phosphorylation	  were	  found	  to	  enhance	  the	  efficacy	  of	  these	  drugs.	  Whilst	  many	  inhibitors	  of	  oxidative	  phosphorylation	  are	  known	  to	   be	   toxic,	   the	   favourable	   safety	   profile	   of	   metformin	   implies	   that	   it	   may	   have	  therapeutic	  potential	  here	  [115].	  	  
Metformin	  and	  Ageing	  The	  biological	  basis	  underlying	  the	  ageing	  process	  is	  a	  central	  mystery	  of	  science,	  and	  its	  resolution	   is	   critical	   for	   developing	  means	   to	  reduce	   the	   harmful	   outcomes	   of	   ageing.	  Recent	   years	   have	   seen	  unprecedented	   progress	   towards	   this	   goal.	   Genetic,	   dietary	  and	  pharmacological	   interventions	   can	   improve	   health	   and	   increase	   lifespan	  in	  laboratory	   model	   organisms:	   the	   nematode	   Caenorhabditis	   elegans,	   the	  fruit	   fly	  
Drosophila	  melanogaster	   and	   the	  mouse	  Mus	  musculus	   [116,	  117].	  These	   interventions	  ameliorate	  the	  ageing	  process	  and	  extend	  healthspan	  by	  protecting	  against	  age-­‐related	  pathology	  and	  loss	  of	  function.	  These	  studies	  provide	  a	  key	  proof-­‐of-­‐principle:	  that	  the	  ageing	   process	   can	   be	   targeted	   to	   achieve	   wide-­‐ranging	   protection	   against	   ageing-­‐associated	  physiological	  decline	  [116,	  117].	  Controlled	  reduction	  of	  food	  intake	  without	  malnutrition	   (dietary	   restriction,	   DR)	   has	   long	   been	   known	   to	   increase	   healthspan	   in	  diverse	  animals	   [118-­‐120],	  and	  drugs	   that	  mimic	  DR	  to	  achieve	   its	  benefits	   in	  humans	  [121].	  In	  this	  section	  we	  will	  provide	  an	  account	  for	  the	  role	  of	  biguanides	  in	  ageing	  as	  potential	  DR	  mimetics.	  	  
Biguanides	  and	  the	  longevity	  of	  C.	  elegans	  	  Several	  studies	  have	  been	  performed	  in	  C.	  elegans	   that	  support	  the	   life	  and	  healthspan	  extending	   properties	   of	   biguanides.	   An	   early	   report	   shows	   that	   administration	   of	  buformin	   at	   0.1	  mg/ml	   throughout	   life	   (including	   the	   larval	   period)	   can	   extend	   adult	  mean	   and	   maximal	   lifespan	   up	   to	   23	   and	   26%,	   respectively	   [122].	   Similarly,	  administration	  of	  metformin	   throughout	   life	   at	   a	  50	  mM	  dose	   can	  also	  extend	  median	  lifespan	  by	  40%	  without	   changes	   in	  maximum	   lifespan	   [123].	   Interestingly,	   lower	  and	  higher	   doses	   of	   metformin	   (10	   and	   100	   mM,	   respectively)	   do	   not	   have	   lifespan	  extending	  properties.	  Recently,	  two	  studies	  showed	  that	  effects	  of	  50	  mM	  metformin	  are	  independent	   of	   its	   administration	  during	   early	  developmental	   time,	   as	  positive	   effects	  
on	  lifespan	  are	  still	  observed	  when	  the	  drug	  is	  administered	  at	  a	  later	  stage	  in	  life	  [90,	  124].	   Similarly,	   phenformin	  over	   a	   range	  of	   concentrations	   such	   as	  1.5,	   3	   and	  4.5	  mM	  can	   extend	   adult	   worm	   mean	   lifespan	   by	   5,	   21	   and	   26%,	   respectively.	   So	   how	   do	  biguanides	   extend	   lifespan	   in	   C.	   elegans?	   Metformin	   has	   an	   intricate	   and	   concerted	  mode-­‐of-­‐action,	  which	  potentially	  accounts	   for	   the	  wide-­‐ranging	  effects	  of	   the	  drug	  on	  host	   physiology.	   We	   have	   shown	   that	   changes	   in	   bacterial	   folate	   and	   methione	  metabolism	   induced	  by	  metformin	  are	   responsible	   for	   the	   life-­‐extending	  properties	  of	  the	   drug	   [90].	   In	   parallel,	   other	   studies	   [123,	   124]	   as	   well	   as	   ours	   [90]suggest	   that	  metformin	   acts	   directly	   as	   a	   metabolic	   stressor,	   potentially	   through	   inhibition	   of	  complex	   I	   of	   the	   respiratory	   chain,	   to	   activate	   an	   oxidative	   stress	   and	   detoxification	  response	   involving	   the	   metabolic	   mediators,	   AMPK	   and	   SKN-­‐1	   (orthologue	   of	  mammalian	   nuclear	   factor	   (erythroid-­‐derived	   2)-­‐like	   2	   or	   NRF-­‐2).	   In	   support	   of	   this	  view,	   administration	   of	   antioxidants	   such	   as	   N-­‐acetyl	   cysteine,	   that	   abrogate	   ROS	  signalling,	   or	  mutations	   in	   AMPK	   and	   SKN-­‐1,	   impair	   the	   development	   of	   an	   adequate	  detoxifying	  response	  and	  abolish	  the	  DR-­‐like	  state	  induced	  by	  the	  effects	  of	  metformin	  on	  bacterial	  metabolism.	  	  	   Metformin	   equally	   displays	   healthspan	   properties.	   Metformin	   reduces	   the	  accumulation	  of	   the	  molecular	  damage	  pigment	   lipofuscin,	  promotes	  youthful	  mobility	  into	   late	   life,	   decreases	   fat	   accumulation	   [123],	   attenuates	   the	   morphological	   decline	  observed	  in	  ageing	  worms	  [124]	  and	  increase	  survival	  rate	  when	  exposed	  to	  long-­‐term	  anoxia	  [125].	  	  
Biguanides	  and	  longevity	  in	  insects	  While	   the	   lifespan	  extending	  properties	  have	  been	  well	  documented	   for	  C.	  elegans,	   the	  same	   does	   not	   apply	   to	   insects.	   Administration	   of	   1,	   2.5	   and	   5	  mM	  metformin	   has	   no	  effect	   on	   lifespan	   on	   males	   or	   females	   Drosophila	   melanogaster	   [126].	   Intriguingly,	  higher	  doses	  of	  metformin	  shortens	  the	  lifespan	  of	  males	  (100	  mM)	  and	  females	  (25,	  50	  and	  100	  mM),	  despite	  robust	  activation	  of	  AMPK	  and	  reduced	  lipid	  stores	  [126].	  This	  is	  a	   striking	   finding	   as	   increased	   levels	   of	   expression	   and	   activation	  of	  AMPK	  have	  been	  shown	   to	   increase	   lifespan	   in	  C.	  elegans	   [127]	   and	  Drosophila	   [128].	   A	  well-­‐described	  feature	  of	  pre-­‐diabetes	  in	  human	  patients	  is	  infection-­‐induced	  hyperglycaemia	  [129].	  In	  a	   fly	   model	   of	   obesity,	   metformin	   administration	   at	   10	   mM	   reduced	   the	   systemic	  infection	   burden	   of	   the	   fungi	  Rhizopus,	   a	   causing	   agent	   of	  mucormycosis	   observed	   in	  diabetic	   patients.	   It	   led	   to	   reduced	   weight	   gain,	   normalised	   glucose	   levels	   due	   to	  infection	  and	   increased	  survival	   rates	   [130].	  Finally,	  5	  mM	  metformin	  had	  a	  beneficial	  effect	   on	   age-­‐related	   changes	   in	   fly	   intestinal	   stem	   cells	   obtained	   from	   the	  midgut	   as	  measured	  by	  a	  decrease	  in	  the	  molecular	  DNA	  damage	  markers	  gH2AX	  foci	  and	  8-­‐oxodG	  [131].	   Recently,	   a	   study	  performed	   in	   the	   cricket	  Acheta	  domesticus	   [132],	   shows	   that	  metformin	   leads	   to	   an	   extension	   in	  mean	   and	  maximal	   lifespan	   of	   organisms	   of	   both	  sexes,	  with	  increases	  in	  43.7%	  and	  23.2	  %	  in	  females	  and	  males,	  respectively.	  	  
Biguanides	  and	  longevity	  in	  rodents	  Several	  studies	  have	  been	  performed	  in	  rodents	  suggesting	  an	  evolutionarily	  conserved	  pro-­‐longevity	   role	   for	   biguanides.	  Work	   by	   Anisimov	   et	   al.	   has	   greatly	   contributed	   to	  such	   advancement	   (reviewed	   in	   [133]).	   Overall,	   metformin	   treatment	   of	   HER-­‐2/neu,	  SHR,	  129/Sv,	  C57BL/6	  and	  B6C3F1	  mice,	  over	  a	  wide-­‐range	  of	  doses	  led	  to	  increases	  in	  lifespan	   ranging	   from	   4	   to	   38%.	   However,	   data	   suggest	   that	   effects	   of	   metformin	   on	  lifespan	  are	  dependent	  on	  genotype,	   gender,	   biguanide	   type,	   dose	   and	  duration	  of	   the	  treatment.	  In	  general,	  the	  later	  the	  starting	  of	  the	  treatment	  the	  less	  lifespan	  benefits	  are	  observed.	   This	   is	   to	   some	   extent	   similar	   to	   the	   results	   obtained	   with	   metformin	  treatment	  on	  C.	  elegans	  survival	  [90,	  123,	  124].	  For	  example,	  treatment	  of	  SHR	  mice	  at	  15	   months	   of	   age	   with	   metformin	   conferred	   no	   longevity	   benefits	   in	   comparison	   to	  starting	  of	   the	   treatment	   at	  3	  months	  of	   age	   (0	  vs	  38%,	   respectively)	   [133].	   Likewise,	  dose	  plays	  an	  important	  role	  in	  lifespan	  extension	  in	  rodents	  as	  observed	  for	  C.	  elegans.	  
Administration	  of	  0.1%	  of	  metformin	  in	  the	  diet	   leads	  to	  a	  lifespan	  extension	  of	  5.83%	  compared	   to	   -­‐14.4%	  when	   1%	   of	   metformin	   is	   given	   to	   C57BL/6	  mice.	   Reduction	   in	  lifespan	  was	   caused	  by	  drug	  nephrotoxicity	   [134].	  Gender	  also	   influences	   the	  effect	  of	  metformin	  on	   lifespan	  as	  biguanide	   treatment	  extended	   the	   lifespan	  of	  129/Sv	   female	  (5%)	  but	  not	  male	  mice	  (-­‐13%)	  [133].	  Phenformin	  administration	  to	  C3H/Sn	  mice	  also	  led	  to	  a	  lifespan	  extension	  of	  21%.	  Interestingly,	  the	  effects	  of	  biguanides	  on	  the	  lifespan	  of	   rats	   are	   not	   as	   pronounced	   as	   the	   ones	   observed	   for	  mice.	   Only	   buformin	   and	   not	  metformin	  or	  phenformin	  extended	  the	   lifespan	  of	  rats.	  Given	  the	  wide-­‐ranging	  effects	  of	  metformin	  in	  host	  physiology,	  which	  includes	  alteration	  of	  body	  weight,	  temperature,	  normalization	  of	  serum	  glucose,	   insulin,	   triglycerides	  and	  cholesterol	   levels,	  regulation	  of	   oestrous	   function	   and	   anti-­‐neoplastic	   effects,	   confounders	   are	   likely	   to	   occur	   and	  influence	   lifespan	  trials	  with	  biguanides	  and	  therefore	  need	  careful	  consideration.	   In	  a	  recent	   study	   by	   Martin-­‐Montalvo	   et	   al.,	   the	   calorie	   restriction	   mimicking	   effects	   of	  metformin	  could	  be	   the	  underlying	  mechanism	  responsible	   for	   the	  effects	   the	  drug	  on	  lifespan	   and	   healthspan	   [134].	   These	   include	   improved	   fitness,	   increased	   insulin	  sensitivity,	   and	   reduced	   low-­‐density	   lipoprotein	   and	   cholesterol	   levels	   without	   a	  decrease	   in	   caloric	   intake.	   At	   the	   molecular	   level,	   metformin	   alters	   gene	   expression	  similarly	   to	   those	   observed	   on	   calorie	   restriction.	   Interestingly,	   metformin	   increases	  AMPK	  activity	  without	  concomitant	  activity	  changes	  in	  the	  respiratory	  chain.	  It	  activates	  an	  antioxidant	  and	  anti-­‐inflammatory	  response	   leading	  to	  reductions	   in	  both	  oxidative	  damage	  accumulation	  and	  chronic	  inflammation.	  	  Altogether,	  the	  collected	  data	  existing	  from	  several	  model	  organisms	  show	  a	  promising	  outlook	   for	   the	   potential	   benefits	   of	   using	   metformin	   as	   an	   anti-­‐ageing	   strategy.	  However,	   further	   investigations	  are	  required	   for	   its	  use	   in	  humans	  as	   its	  definite	  anti-­‐ageing	  mechanism	  is	  still	  not	  fully	  disclosed.	  	  
Metformin	  and	  longevity	  in	  humans	  To	   date	   no	   long-­‐term	   longitudinal	   survival/mortality	   studies	   have	   been	   performed	   in	  healthy	   patients	   with	   metformin	   subjected	   to	   metformin	   therapy.	   A	   10-­‐year	   long	  randomised	   clinical	   trial	   of	  metformin	   therapy	   in	  T2D	  overweight/obese	  patients	   (UK	  Prospective	   Diabetes	   Study	   –	   UKPDS-­‐O)	   shows	   long-­‐term	   beneficial	   effects	   on	   health	  and	   survival	   [50],	   reducing	   cardiac	   and	   all-­‐cause	   mortality	   of	   patients	   on	   metformin	  versus	   usual	   care.	   Indeed,	   the	   benefits	   of	   metformin	   on	   host	   metabolism	   have	   been	  observed	  even	  after	   cessation	  of	   treatment,	   the	   so-­‐called	   “legacy	   effect”.	  However,	   the	  molecular	  mechanisms	  by	  which	  metformin	  promotes	   these	   long-­‐term	  positive	  effects	  on	   mortality	   [50],	   independent	   of	   glycaemic	   control,	   remain	   unknown.	   Interestingly,	  another	  long-­‐term	  UK	  Prospective	  Diabetes	  Study	  –	  UKPDS-­‐S	  (6.6	  years),	  of	  metformin	  plus	   sulfonylurea	   vs	   sulfonylurea	   in	   a	   mixed	   group	   of	   non-­‐overweight	   and	  overweight/obese	   T2D	   patients	   showed	   possible	   harmful	   effects	   of	  metformin	   (when	  combined	  with	  sulfonylurea)	  [47].	  In	  a	  more	  recent	  meta-­‐analysis	  of	  randomised	  clinical	  trials	  of	  metformin	  therapy	  in	  individuals	  with	  and	  without	  diabetes,	  which	  include	  the	  two	  UKPDS	  studies,	  Stevens	  et	  al.,	  showed	  no	  effects	  on	  all-­‐cause	  mortality	  [71].	  Overall,	  based	  on	   the	   information	   learned	   from	   lower	  model	   organisms	   and	   reviewed	  here,	   in	  order	  to	  ascertain	  the	  long-­‐term	  beneficial	  effects	  of	  metformin	  on	  human	  longevity	  new	  studies	  targeting	  healthy	  younger	  patients	  are	  warranted.	  	  	  
Metformin	  and	  the	  Microbiota	  Living	  organisms	  rarely	  exist	   in	   isolation	  but	  rather	   in	   intimate	  association	  with	  other	  species,	  in	  particular	  microorganisms	  [135].	  The	  intestine	  is	  home	  to	  the	  majority	  of	  the	  microbes	   that	   inhabit	   the	   human	   body	   and	   these	   vast	   populations	   of	  microorganisms	  collectively	   designated	   as	   the	   “forgotten	   organ”,	   the	   microbiota,	   is	   involved	   in	   many	  metabolic	   processes	   with	   important	   consequences	   for	   host	   physiology	   and	   the	  modulation	   of	   metabolic	   phenotypes	   [136].	   Recent	   reports	   provide	   a	   link	   between	  
alterations	  to	  the	  microbiota	  in	  the	  gastrointestinal	  tract	  (caused	  by	  changes	  in	  diet	  and	  environmental	  conditions	  such	  as	  antibiotics)	  and	  nutrition-­‐related	  syndromes	  such	  as	  obesity,	  T2D,	  metabolic	  syndrome,	  cancer	  and	  ageing	  [137,	  138],	  suggesting	  that	  the	  gut	  microbiota	  could	  act	  as	  a	  potential	  biomarker	   for	  host	  health.	  Therefore,	  host-­‐targeted	  drugs,	   such	  as	  metformin,	   commonly	  used	   to	   treat	  metabolic	  diseases	   associated	  with	  microbiota	  dysfunction	  may	  act	  on	  the	  physiology	  of	  the	  bacterial	  populations	  to	  exert	  their	  effects	  on	  the	  host.	  Does	  the	  gut	  microbiota	  influence	  the	  therapeutic	  potential	  of	  metformin	   and/or	   explain	   its	   side-­‐effects	   in	   mammals?	   To	   what	   extent	   microbiota	  mediate	   the	  effects	  of	  metformin	  on	  metabolic	  disease	   remains	  an	  open	  question.	  One	  possibility	  is	  that	  metformin	  alters	  the	  structure	  and/or	  function	  of	  the	  microbiota	  in	  a	  way	   that	   promotes	  metabolic	   health.	   An	   increasing	   number	   of	   recent	   reports	   support	  this	  interpretation	  and	  will	  be	  discussed	  in	  this	  section.	  	  
Metformin	  alters	  microbial	  metabolism	  and	  regulates	  C.	  elegans	  physiology	  The	   nematode	   C.	   elegans	   establishes	   a	   beneficial	   interaction	   with	   E.	   coli	   bacteria,	   a	  relationship	   that	   is	   similar	   but	   far	   simpler	   than	   the	   vast	   communities	   of	   ‘healthy’	  bacteria	  residing	  in	  the	  human	  gut.	  We	  have	  demonstrated	  that	  metformin	  exerts	  DR	  on	  
C.	  elegans	  by	  altering	  bacterial	  folate	  and	  methionine	  metabolism	  [90],	  providing	  for	  the	  first	   time	   a	  mechanistic	   explanation	   for	   the	   effects	   of	  metformin	   on	   the	   host	   through	  action	  on	  its	  microbiota.	  In	  C.	  elegans,	  metformin	  slows	  down	  the	  ageing	  process	  only	  if	  bacteria	  are	  present	  and	  in	  a	  dose-­‐dependent	  manner,	  an	  effect	  which	  is	  proportional	  to	  its	  effects	  on	  microbial	  metabolism	  and	  the	  bacterial	  strain	  with	  which	   the	  worms	  are	  co-­‐cultured	   [90].	   Remarkably,	  metformin	   can	   also	   cause	   folate	   [139]	   and	   vitamin	  B12	  deficiency	  [140]	  and	  increase	  plasma	  homocysteine	  levels	  [141]	  in	  humans.	  	  
	  
Metformin	  disrupts	  intestinal	  fluid	  homeostasis	  in	  flies	  The	  gut	  of	  Drosophila	  melanogaster	   is	   recently	  becoming	  one	  of	   the	  most	  well	   studied	  organs	  in	  fly	  research.	  Similarly	  to	  humans,	  flies	  show	  an	  important	  conservation	  in	  gut	  functions.	  Fluid	  retention,	  absorption,	  intestinal	  peristalsis,	  intestinal	  transit,	  defecation	  rate	   and	   nature	   of	   excreta	   are	   also	   subject	   to	   complex	   homeostatic	   regulation	   [142].	  Recent	  studies	  show	  that	  the	  Drosophila	  microbiome	  modulates	  host	  development	  and	  metabolic	  homeostasis	  via	  insulin	  signalling	  [143]	  and	  mTOR	  signalling	  [144].	  However,	  the	   precise	   role	   of	   bacteria	   in	   gut	   physiology	   remains	   unclear.	   Given	   that	   metformin	  leads	   to	   gastrointestinal	   upset	   when	   administered	   to	   diabetic	   patients,	   Slack	   et	   al.	  investigated	   if	   metformin	   alters	   intestinal	   physiology	   in	   ageing	   flies.	   Using	   an	   assay	  recently	  developed	  to	  evaluate	  intestinal	  physiology	  through	  examination	  of	  fly	  excreta	  [145],	   these	   authors	   showed	   that	   100	   mM	   metformin	   lead	   to	   changes	   in	   intestinal	  homeostasis	  causing	  fluid	  imbalances	  resulting	  in	  more	  concentrated	  faecal	  deposits	  in	  a	   possible	   attempt	   to	   preserve	   water.	   Possibly,	   at	   such	   elevated	   concentrations,	  metformin	   acting	   as	   a	   metabolic	   stressor	   can	   produce	   acid	   in	   excess	   that	   is	  counterbalanced	  by	  the	  gut.	  In	  fact,	  the	  hindgut	  of	  flies	  has	  the	  ability	  to	  adjust	  the	  pH	  of	  intestinal	  material	  before	  excretion	   in	   response	   to	  both	   internal	   (e.g.	   reproductive)	  or	  external	   (e.g.	   nutrients)	   signals	   [145].	   Unexpectedly,	  metformin	   treatment	   in	   flies	   did	  not	   lead	   to	   increased	   lifespan	   extension	  despite	   activation	  of	  AMPK.	  Whether	   lifespan	  extension	  in	  flies	   is	  also	  dependent	  on	  metformin	  sensitivity	  of	  gut	  flora	  remains	  to	  be	  tested.	  	  
Metformin	  action	  on	  gut	  function	  in	  rodents	  Studies	   performed	   in	  mice	   show	   that	  metformin	   accumulates	   in	   the	   intestine	   at	   very	  high	   concentrations	   [39],	   and	   this	   could	  possibly	   explain	   effects	   of	  metformin	  on	  host	  metabolism.	   Evidence	   collected	   in	   rodents	   also	   suggests	   that	   the	   intestine	   is	   a	   major	  organ	   regulating	   the	   action	   of	   metformin.	   Data	   show	   that	   metformin	   not	   only	   delays	  glucose	   absorption	   along	   the	   intestinal	   tract	   [43]	   but	   also	   increases	   its	   utilisation	  through	  non-­‐oxidative	  anaerobic	  metabolism	  [146].	  Lactate	  as	  a	  product	  of	  non-­‐aerobic	  
metabolism	   can	   be	   delivered	   to	   the	   liver	   through	   the	   portal	   vein	   and	   utilised	   as	   a	  substrate	  for	  gluconeogenesis.	  Therefore,	  the	  intestine	  makes	  an	  important	  contribution	  to	   the	   glucose-­‐lowering	   effects	   of	   metformin	   providing	   at	   the	   same	   time	   a	   safeguard	  mechanism	  against	  hypoglycaemia	  [147].	  	  Most	  of	  the	  microbes	  that	  co-­‐exist	  within	  the	  host	  also	  reside	  in	  the	  intestine	  and	  are	   therefore	   under	   selective	   pressure	   at	   high	   concentrations	   of	  metformin.	   T2D	   and	  obesity	   are	   characterised	   by	   structural	   and	   functional	   changes	   in	   the	   microbial	  populations	  in	  the	  gut,	  an	  inflammatory	  state,	  and	  gut	  barrier	  disruption	  also	  known	  as	  leaky	   gut.	   There	   are	  many	   similarities	   between	   the	   role	   of	  microbiota	   and	  metformin	  effects	  on	  obesity	  and	  blood	  glucose	  regulation.	  It	  is	  therefore	  plausible	  to	  assume	  that	  common	  mechanisms	  are	  at	  play	  and	  metformin	  has	  a	  direct	  or	  indirect	  interaction	  with	  functions	  of	  the	  microbiota	  on	  the	  host	  to	  accomplish	  its	  anti-­‐diabetic	  effects.	  	   Two	  recent	  studies	  by	  Shin	  et	  al.	  and	  Lee	  et	  al.	  show	  that	  metformin	  treatment	  of	  mice	   on	   a	   high-­‐fat	   diet	   improves	   markers	   of	   metabolic	   disorders	   and	   provokes	   an	  alteration	  in	  the	  structure	  of	  faecal	  microbiota	  towards	  of	  that	  of	  mice	  feeding	  a	  normal	  chow	  diet	   [148,	  149].	  Using	  metagenomic	  analysis,	   these	  studies	  show	  that	  metformin	  causes	   a	   profound	   shift	   in	   specific	   subsets	   of	   bacterial	   taxa.	   The	   microbial	   change	   in	  mice	  treated	  with	  metformin	  was	  accompanied	  by	  an	  increase	  of	  the	  genus	  Akkermansia	  spp.	   [148,	   149].	   Metformin	   led	   to	   an	   increase	   of	   goblet	   cells	   producers	   of	   mucin,	   a	  nutrient	   source	   for	   the	   mucin-­‐degrading	   bacteria	   Akkermansia	   municiphila.	   In	   fact,	  probiotic	   administration	   of	   this	   bacterial	   strain	   or	   metformin	   is	   associated	   with	   an	  improved	   metabolic	   profile,	   reducing	   metabolic	   endotoxemia,	   adipose	   tissue	  inflammation,	   and	   improved	   glycaemic	   control	   insulin	   resistance	   [149,	   150].	   Further	  studies	   to	   determine	   a	   causal	   link	   between	  metformin	   treatment	   and	  Akkermansia	   to	  promote	   its	   anti-­‐diabetic	   effects	   are	   therefore	   warranted.	   An	   increase	   in	   Lactobacilli	  populations	   was	   also	   observed	   in	   high-­‐fat	   diet	   mice	   treated	   with	   metformin.	  
Lactobacillus	   is	   one	   of	   the	   many	   bacteria	   that	   can	   utilise	   glucose	   to	   produce	   lactate.	  Notably,	   effects	   of	   metformin	   in	   improving	   glucose	   homeostasis	   in	   high-­‐fat	   mice	   are	  abolished	   through	   a	   cocktail	   of	   broad-­‐spectrum	   antibiotics	   [149].	   These	   data	   suggest	  that	  gut	  microbiota	  is	  a	  target	  of	  metformin	  to	  produce	  its	  effects	  on	  host	  physiology.	  It	  is	  possible	   that	  extra	   lactate	  production	   in	   the	   intestine	  by	  metformin	  could	  derive,	   in	  addition	   to	   its	   production	   through	   non-­‐oxidative	  metabolism	   by	   intestinal	   cells,	   from	  lactate	  producing	  bacteria	  that	  utilise	  glucose.	  Alternatively,	  increased	  lactate	  and	  other	  gluconeogenic	  precursors	  such	  as	  pyruvate	  and	  alanine	  by	  metformin	  [151],	  in	  addition	  to	  sustaining	  gluconeogenesis	  during	   fasting	  and	  protect	  against	  hypoglycaemia,	   could	  modify	   the	   structure	   of	   the	  microbiota	   by	   providing	   new	   energy	   substrates	   favouring	  specific	   microorganisms.	   Whether	   changes	   in	   the	   structure	   of	   the	   microbiota	   result	  directly	   from	   high	   concentrations	   of	   the	   drug	   in	   the	   intestine,	   or	   indirectly	   by	  metabolites	  resulting	  from	  the	  host	  upon	  metformin	  treatment	  remains	  to	  be	  elucidated.	  	  	   In	   a	   study	   performed	   in	   rats,	   Pyra	   et	   al.	   showed	   that	   the	   novel	   combination	  therapy	  of	  prebiotic	  fibres	  such	  as	  oligofructose	  and	  metformin	  improves	  the	  metabolic	  profile	   of	   high-­‐fat	   diet	   induced	   obese	   rats.	   The	   combined	   action	   of	   metformin	   and	  oligofructose	   has	   an	   improved	   effect	   over	   each	   individual	   treatment	   alone	   on	   body	  weight,	  hepatic	  triglycerides,	  secretion	  of	  glucose-­‐dependent	  insulinotropic	  polypeptide	  and	  leptin,	  and	  AMPK	  activation.	  Effects	  of	  this	  therapeutic	  approach	  on	  gut	  microbiota	  were	   also	   evaluated	   in	   this	   study.	   As	   expected,	   oligofructose	   treatment	   increased	  significantly	  bifidogenic	  bacteria	  such	  as	  Bifidobacterium	  spp.	  [152].	  	  These	  studies	  show	  that	  metformin	  administration	   to	  rodents	  on	  high-­‐fat	  diets	  induces	  significant	  modifications	  in	  the	  structure	  of	  the	  microbial	  populations	  in	  the	  gut.	  This	  leads	  to	  a	  new	  understanding	  of	  how	  metformin	  could	  affect	  metabolism	  to	  lower	  glycaemia	   through	   targeting	   the	  microbiota.	   However,	   further	   studies	   are	   required	   to	  fully	  elucidate	  what	  effect	  this	  has	  upon	  the	  host.	  	  
Metformin	  action	  on	  the	  human	  intestine	  and	  microbiota	  
Most	   anti-­‐diabetic	   drugs	  have	   therapeutic	   doses	   in	   the	  microgram/milligram	   range	   to	  reduce	   hyperglycaemia	   in	   T2D	   patients.	   Interestingly,	   effective	   metformin	   doses	   can	  reach	   up	   to	   2.5	   grams	   per	   day	   [153].	   The	   intestine	   is	   the	   main	   tissue	   for	   metformin	  absorption	  [154]	  and	  accumulation	  [155]	  in	  humans	  and	  other	  animals.	  Absorption	  time	  T1/2	   is	   estimated	   to	   be	   between	  0.9	   to	   2.6	   h,	   and	   is	   affected	  by	   food	   intake	  which	   can	  delay	   the	  process	  by	  35	  min	   [156].	  Metformin	   is	   stable,	  does	  not	  bind	   to	  proteins	  and	  has	   a	   bioavailability	   of	   50-­‐60%.	   The	   drug	   reaches	   its	   maximum	   concentration	   in	  peripheral	  plasma	  approximately	  2	  h	  after	  oral	  ingestion,	  is	  eliminated	  from	  the	  plasma	  rapidly	  with	  a	  T1/2	  of	  1.7	  to	  4.5	  h	  and	  excreted	  unchanged	  either	   in	  the	  urine	  or	   in	  the	  faeces	  [157].	  Similar	   to	  what	   is	  observed	   in	  rodents,	  high	  concentrations	  of	  metformin	  also	  accumulate	  in	  the	  human	  intestine	  [155].	  In	  fact,	  the	  concentration	  of	  metformin	  in	  the	  jejunum	  can	  attain	  30-­‐300	  fold	  its	  concentration	  in	  the	  plasma	  [38]	  or	  other	  tissues	  [39].	  Intralumenal	  concentrations	  in	  the	  range	  of	  20	  mM	  after	  administration	  of	  an	  850	  mg	   dose	   of	  metformin	   have	   been	   observed	   in	   the	   intestine	   of	   diabetic	   patients	   [158].	  Therefore,	   it	   is	   likely	   that	   the	   effects	   of	   metformin	   on	   the	   intestinal	   tissue	   might	   be	  different	  to	  some	  extent	  in	  comparision	  to	  other	  tissues	  and	  also	  be	  responsible	  for	  the	  observed	  side-­‐effects	  associated	  with	  this	  drug.	  	   The	   most	   common	   side-­‐effects	   associated	   with	   metformin	   administration	  include	  gastrointestinal	  upset	  and	  lactic	  acidosis.	  However,	  occurrence	  of	  lactic	  acidosis	  with	   metformin	   is	   an	   uncommon	   event	   (3-­‐9/100,000	   patient-­‐years)	   and	   very	   rarely	  causes	  death	  (2-­‐4/100,000	  patient-­‐years)	  [159].	  On	  the	  other	  hand,	  disturbances	  of	  the	  gastrointestinal	   tract	   appear	   soon	   after	   the	   treatment	   is	   initiated,	   diminish	   over	   long	  periods	   of	   therapy	   and	   stop	   if	   the	   treatment	   is	   discontinued.	   These	   mainly	   include	  diarrhoea	  and	  other	  minor	  disorders	  such	  as	  abdominal	  pain	  with	  cramps	  and	  swelling,	  vomiting,	   nausea,	   dyspepsia,	   dysgeusia,	   flatulence	   and	   constipation.	   These	   combined	  digestive	   disorders	   can	   affect	   up	   to	   29%	   of	   the	   patients	   treated	   with	   up	   to	   2.5	   g	  metformin/day,	   leading	   to	   discontinuation	   of	   metformin	   therapy	   in	   10%	   of	   these	  patients	   [160].	   While	   these	   gastrointestinal	   effects	   are	   widely	   observed	   in	   patients	  taking	   metformin,	   the	   molecular	   mechanisms	   underlying	   such	   responses	   are	   still	  unclear.	   Only	   a	   few	   reports	   have	   addressed	   this	   question	   and	   some	   possible	  mechanisms	   have	   been	   put	   forward	   and	   reviewed	   by	   Bouchoucha	   et	   al.	   [161].	   These	  include	  changes	   in	  serotonin	  metabolism,	  changes	   in	   incretin	  and	  glucose	  metabolism,	  and	   alteration	   of	   bile	   acid	   metabolism.	   However,	   none	   fully	   explains	   the	  pathophysiological	  effects	  of	  metformin	  gastrointestinal	  side-­‐effects.	  Recently,	   new	   studies	   suggest	   that	  metformin	   affects	  microbial	  metabolism	   in	  the	  gut.	  This	  is	  a	  new	  interesting	  hypothesis	  that	  could	  possibly	  explain	  inter-­‐individual	  effects	  of	  metformin	   in	  digestive	  disorders.	  Karlsson	  et	  al.	   evaluated	   the	  structure	  and	  function	   of	   faecal	   microbiota	   of	   a	   cohort	   of	   145	   70-­‐year	   old	   European	   women	   with	  normal,	   impaired	   and	   diabetic	   glucose	   control	   with	   metformin	   [162].	   Metagenomic	  analysis	   of	   T2D	   human	   patients	   treated	   with	   metformin	   show	   increased	   levels	   of	  Enterobacteriaceae	  (e.g.	  Escherichia,	  Shigella,	  Klebsiella	  and	  Salmonella)	  and	  decreased	  levels	  of	  Clostridium	  and	  Eubacterium.	   Interestingly,	  there	  was	  a	  significant	  correlation	  of	  E.	   coli	   levels	   and	   glucagon-­‐like	   peptide	   levels.	   Secretion	   of	   glucagon	   like	   peptide	   is	  reduced	   in	   obese	   and	   T2D	   patients	   [163]	   and	   metformin	   increases	   its	   levels	   in	   the	  plasma	  [164].	  According	  to	  the	  authors	  of	  this	  study,	  changes	  of	  structure	  and	  function	  of	  the	  microbiota	  in	  T2D	  patients	  treated	  with	  metformin	  might	  be	  a	  consequence	  of	  the	  treatment	  and	  increased	  glucose	  availability	  in	  the	  intestinal	  lumen.	  	   	  Other	   side-­‐effects	   associated	   with	   long-­‐term	   metformin	   therapy	   that	   could	  possibly	   be	   explained	   by	   the	   effects	   of	  metformin	   on	  microbiota	   are	   vitamin	  B12	   and	  folate	   deficiency	   [139]	   and	   alterations	   in	   bile	   acid	  metabolism	   [165].	   Bacteria	   such	   as	  
Bifidobacterium	   are	   important	   suppliers	   of	   vitamins	   to	   their	   host.	   In	   addition,	   several	  anaerobic	   bacteria	   are	   involved	   in	   the	   transformation	   of	   bile	   acids	   in	   the	   intestine,	  whose	  main	  function	  is	  to	  facilitate	  the	  metabolism	  of	  dietary	  fat	  and	  absorption	  of	  fat-­‐soluble	  vitamins	  [166].	  Recently,	  Napolitano	  et	  al.	  have	  characterised	  these	  interactions	  
in	  human	  patients	  by	  relating	  glycaemic	  control,	  bile	  acid	  metabolism	  and	  microbiome	  alteration	  [165].	  These	  authors	  find	  important	  changes	  in	  the	  levels	  of	  members	  of	  the	  microbiota	  (Firmicutes/Bacteriodetes),	  changes	  in	  the	  entero-­‐hepatic	  levels	  of	  bile	  acids	  (e.g.	  cholic	  acid)	  and	  entero-­‐endocrine	  hormones	  (glucagon-­‐like	  peptide-­‐1	  and	  peptide	  YY).	   Altogether,	   these	   suggest	   a	  mechanistic	   link	   between	   bile	   acid-­‐induced	  microbial	  changes	  and	  glycemic	  control	   in	  T2D	  patients.	   Interestingly,	  cholic	  acid	  administration	  to	   rodents	   produces	   similar	   changes	   in	   the	   relative	   abundance	   of	   Firmicutes	   and	  Bacteroidetes	  [167].	  Altogether,	  new	  reports	  support	  the	  evidence	  from	  earlier	  studies	  showing	   that	   intravenous	  administration	  of	  metformin	  whilst	  attaining	   therapeutically	  effective	   blood	   concentrations	   do	   not	   improve	   blood	   glucose	   in	   stark	   contrast	   to	   oral	  administration	   of	   the	   drug	   [168,	   169].	   However,	   how	   exactly	   metformin	   affects	   the	  intestine	  and	  the	  microbiota	  contained	   in	   it	   is	  still	  unclear.	  Therefore,	  new	  studies	  are	  required	   to	  understand	  how	  metformin	  affects	  physiology	  and	  re-­‐evaluate	   its	  mode	  of	  action.	  	  	  
Conclusion	  Metformin	   has	   been	   used	   as	   a	   safe	   and	   effective	   treatment	   for	   T2D	   for	   over	   half	   a	  century,	  yet	  the	  precise	  mechanism	  of	  action	  of	  this	  drug	  still	  remains	  elusive.	  The	  anti-­‐hyperglycaemic	   properties	   of	   metformin	   are	   chiefly	   mediated	   by	   the	   suppression	   of	  hepatic	  gluconeogenesis	  and	  it	   is	  generally	  accepted	  that	  this	  is	  achieved	  via	  inhibition	  of	   complex	   I	   in	   the	   mitochondrial	   respiratory	   chain.	   The	   subsequent	   reduction	   in	  cellular	  energy	  status	  has	  been	  shown	  to	  directly	   impede	  gluconeogenic	   flux,	   interfere	  with	  glucagon	  signalling	  and	  promote	  activation	  of	  the	  major	  metabolic	  regulator	  AMPK,	  although	   which	   of	   these	   make	   the	   greatest	   contribution	   to	   metformin’s	   therapeutic	  effects	   is	   a	   subject	   of	   debate.	   Moreover,	   it	   is	   becoming	   increasingly	   apparent	   that	  complex	   I	   is	   not	   the	   only	  molecular	   target	   of	  metformin;	   for	   example,	   it	   has	   recently	  been	   confirmed	   that	   metformin	   inhibits	   mGPD.	   It	   is	   highly	   probable	   that	   additional	  targets	  will	  be	  identified	  in	  the	  near	  future.	  Our	  work	  in	  C.	  elegans	  serves	  as	  a	  reminder	  that	  it	  is	  necessary	  to	  consider	  the	  effect	  of	  drugs	  not	  only	  on	  the	  individual	  but	  also	  on	  their	  microbiota.	  Very	  little	  is	  currently	  known	  about	  the	  bacterial	  targets	  of	  metformin	  and	   it	   is	   possible	   that	   the	   microbiota	   could	   regulate	   some	   of	   its	   effects	   on	   host	  physiology	   via	   private	   mechanisms.	   This	   undoubtedly	   warrants	   further	   investigation.	  Currently,	  metformin	  is	  only	  approved	  as	  a	  treatment	  for	  T2D	  however	  in	  recent	  years,	  a	  vast	  number	  of	   studies	  have	  highlighted	   the	   therapeutic	  potential	  of	  metformin	   in	   the	  context	  of	  other	  diseases.	  In	  particular,	  metformin	  has	  shown	  promise	  as	  a	  treatment	  for	  CVD	   and	   cancer.	   The	   various	   mechanisms	   proposed	   to	   account	   for	   these	   beneficial	  effects	  have	  been	  outlined	   in	   this	   review,	   although	   there	  are	   a	  number	  of	   outstanding	  issues	   that	  must	  still	  be	   resolved.	  Ultimately	  a	  greater	  understanding	  of	   the	  molecular	  pathways	  involved	  will	  help	  to	  guide	  novel	  applications	  of	  metformin.	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  Legends	  
Figure	  1	  Proposed	  mechanisms	  of	  metformin	  action	  in	  Type	  2	  diabetes.	  Metformin	  enters	   the	   hepatocyte	   through	   OCT1	   and	   accumulates	   in	   the	   mitochondria	   where	   it	  inhibits	   Complex	   I.	   This	   leads	   to	   a	   reduction	   in	   ATP	   and	   concomitant	   rise	   in	   AMP.	  Elevated	  AMP	  levels	  lead	  to	  activation	  of	  AMPK,	  although	  metformin	  may	  also	  promote	  AMPK	  activation	  in	  a	  direct	  manner.	  AMPK	  inhibits	  gluconeogenic	  gene	  transcription	  by	  preventing	   formation	   of	   the	   CREB:CBP:CRTC2	   complex,	   both	   directly	   and	   via	   SIRT1.	  
Furthermore,	   AMPK	   inhibits	   lipogenesis	   through	   ACC,	   ChREBP	   and	   SREBP	  phosphorylation,	  which	  helps	  to	  improve	  insulin	  sensitivity.	  Several	  AMPK-­‐independent	  mechanisms	  of	  metformin	  action	  also	  exist.	  The	  reduction	  in	  cellular	  energy	  status	  can	  directly	  inhibit	  gluconeogenic	  flux.	  Additionally,	  increased	  AMP	  has	  an	  inhibitory	  effect	  on	   adenylate	   cyclase	   leading	   to	   decreased	   cAMP	   production.	   This	   in	   turn	   reduces	   the	  activity	  of	  PKA	  and	  its	  downstream	  targets,	  which	  include	  CREB.	  Metformin	  also	  inhibits	  mGPD.	   This	   prevents	   glycerol	   from	   contributing	   to	   gluconeogenesis	   and	   increases	   the	  cytosolic	   redox	   state,	   which	   in	   turn	   makes	   the	   conversion	   of	   lactate	   to	   pyruvate	  unfavourable	  thus	  limiting	  the	  use	  of	  lactate	  as	  a	  gluconeogenic	  substrate.	  	  	  
Figure	  2.	  Proposed	  mechanisms	  to	  explain	  the	  anticancer	  effects	  of	  metformin.	  At	  the	  systemic	  level	  metformin	  may	  inhibit	  tumour	  development	  by	  reducing	  insulin/IGF-­‐1	   signalling,	   preventing	   the	   release	   of	   proinflammatory	   cytokines	   through	   NF-­‐kB	   and	  enhancing	   the	   immune	   response	   (mediated	   by	   natural	   killer	   cells	   (NK	   cells)	   and	  cytolytic	   T	   cells	   (T-­‐cells))	   to	   cancer	   cells.	   Metformin	   also	   has	   direct	   effects	   in	   cancer	  cells,	  many	  of	  which	  are	  mediated	  by	  AMPK.	  When	  activated,	  AMPK	  disrupts	  cancer	  cell	  energy	   metabolism	   by	   inhibiting	   fatty	   acid	   synthesis	   (inhibition	   of	   acetyl-­‐CoA	  carboxylase	  (ACC))	  and	  suppressing	  the	  Warburg	  phenotype	  mediated	  by	  the	  action	  of	  the	   hypoxia-­‐induced	   factor	   (HIF-­‐1)	   on	   the	   glycolytic	   enzymes	   pyruvate	   kinase	   (PDK)	  and	   pyruvate	   dehydrogenase	   (PDH).	   AMPK	   may	   also	   block	   folate	   and	   methionine	  metabolism,	   which	   is	   required	   for	   nucleotide	   synthesis.	   AMPK	   downregulates	   the	  oncogene	   c-­‐MYC	   by	   inducing	   the	   expression	   of	   Dicer	   and	   upregulates	   the	   tumour	  suppressor	  p53	  by	   inhibiting	   its	  negative	  regulator	  MDMX.	  Furthermore,	  AMPK	  blocks	  the	   mTORC1	   signalling	   pathway	   by	   inhibiting	   Raptor	   and	   activating	   TSC2.	   AMPK	  independent	  mechanisms	  have	  also	  been	  described.	  Metformin	  can	  protect	  against	  DNA	  damage	   by	   inhibiting	   complex	   I	   and	   suppressing	   ROS	   production.	   Metformin	   also	  inhibits	  hexokinase	  activity	  and	  impairs	  glucose	  uptake.	  Metformin	  can	  block	  mTORC1	  signalling	  in	  the	  absence	  of	  AMPK	  via	  inhibition	  of	  Rag	  GTPases.	  Additionally,	  metformin	  reduces	   levels	   of	   the	   cell	   cycle	   regulator	   Cyclin	   D1	   in	   a	   p53	   and	   REDD1	   dependent	  manner.	   Finally,	   metformin	   promotes	   apoptosis	   by	   downregulating	   the	   Stat3/Bcl-­‐2	  pathway	  through	  release	  of	  cytochrome	  C	  and	  also	  promotes	  autophagy.	  	  
Figure	  3.	   Effects	   of	  metformin	   in	   gut	  physiology	   to	   regulate	   type	  2	  diabetes	   and	  
survival	   in	   model	   organisms	   and	   humans.	   Metformin	   increases	  C.	   elegans	   lifespan	  when	   co-­‐cultured	  with	   a	   sensitive	   but	   not	   a	   tolerant	  E.	  coli	   strain.	   In	  Drosophila,	   high	  concentrations	   of	   metformin	   lead	   to	   intestinal	   dyshomeostasis	   and	   increased	  concentration	  of	   faecal	  output	   that	  correlates	  with	  an	  observed	  shortening	  of	   lifespan.	  Metformin	   normalises	   the	   gut	   microbiota	   of	   rodents	   on	   a	   high-­‐fat	   diet	   and	   improves	  glucose	   homeostasis	   due	   to	   effects	   on	   the	   gut	   microbiota.	   In	   T2D	   diabetic	   patients,	  metformin	  promotes	  weigh	  loss	  and	  improved	  glucose	  tolerance	  either	  by	  reducing	  gut	  glucose	  uptake	  or	  by	  direct	  alterations	  of	  the	  gut	  microbiota	  which	  can	  ultimately	  lead	  to	  increased	  survival.	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